{"id":16668,"date":"2024-09-27T18:54:20","date_gmt":"2024-09-27T16:54:20","guid":{"rendered":"https:\/\/inmuno.es\/?page_id=16668"},"modified":"2024-09-27T18:54:20","modified_gmt":"2024-09-27T16:54:20","slug":"cancer-immunology-research","status":"publish","type":"page","link":"https:\/\/inmuno.es\/index.php\/cancer-immunology-research\/","title":{"rendered":"Cancer Immunology Research"},"content":{"rendered":"<ul class=\"wp-block-latest-posts__list is-grid columns-4 has-dates has-author wp-block-latest-posts\"><li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/17\/cd4-t-cells-play-distinct-roles-during-the-priming-versus-effector-phases-of-immune-checkpoint-therapy-dependent-tumor-elimination-by-cd8-t-cells\/\">CD4+ T cells play distinct roles during the priming versus effector phases of immune checkpoint therapy-dependent tumor elimination by CD8+ T cells<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-17T00:54:22+02:00\" class=\"wp-block-latest-posts__post-date\">17 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jul 16. doi: 10.1158\/2326-6066.CIR-25-1652. Online ahead of print. ABSTRACT It is well established that CD4\u207a T cells play a critical role in facilitating immune checkpoint therapy (ICT). Although CD4+ T-cell function in lymph nodes during CD8\u207a T-cell priming has been well investigated, their requirement at the effector phase in the tumor &#8230; <a title=\"CD4+ T cells play distinct roles during the priming versus effector phases of immune checkpoint therapy-dependent tumor elimination by CD8+ T cells\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/17\/cd4-t-cells-play-distinct-roles-during-the-priming-versus-effector-phases-of-immune-checkpoint-therapy-dependent-tumor-elimination-by-cd8-t-cells\/\" aria-label=\"Read more about CD4+ T cells play distinct roles during the priming versus effector phases of immune checkpoint therapy-dependent tumor elimination by CD8+ T cells\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/17\/elevated-chaf1a-suppresses-type-i-interferon-production-and-causes-immunotherapy-resistance-in-esophageal-squamous-cell-carcinoma\/\">Elevated CHAF1A suppresses type I interferon production and causes immunotherapy resistance in esophageal squamous cell carcinoma<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-17T00:54:22+02:00\" class=\"wp-block-latest-posts__post-date\">17 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jul 16. doi: 10.1158\/2326-6066.CIR-25-1617. Online ahead of print. ABSTRACT In esophageal squamous cell carcinoma (ESCC), chemoradiotherapy potentiates the effects of immune checkpoint inhibitors (ICIs) by activating the tumor-intrinsic innate immune response. However, ESCC cells frequently suppress this activation, which contributes to the high rates of immunotherapy resistance (70-80%) observed clinically. Thus, &#8230; <a title=\"Elevated CHAF1A suppresses type I interferon production and causes immunotherapy resistance in esophageal squamous cell carcinoma\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/17\/elevated-chaf1a-suppresses-type-i-interferon-production-and-causes-immunotherapy-resistance-in-esophageal-squamous-cell-carcinoma\/\" aria-label=\"Read more about Elevated CHAF1A suppresses type I interferon production and causes immunotherapy resistance in esophageal squamous cell carcinoma\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/15\/tim-3-sustains-tumor-treg-stability-and-function-limiting-checkpoint-blockade-therapy-efficacy\/\">Tim-3 Sustains Tumor Treg Stability and Function, Limiting Checkpoint Blockade Therapy Efficacy<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-15T19:30:00+02:00\" class=\"wp-block-latest-posts__post-date\">15 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jul 15. doi: 10.1158\/2326-6066.CIR-25-0687. Online ahead of print. ABSTRACT Regulatory T cells (Treg) act as a powerful barrier to effective antitumor immunity. Although manipulating Treg is a promising anticancer strategy, doing so while sparing general immune tolerance has been a challenge. Identifying factors specifically expressed in tumor-infiltrating Treg is therefore important &#8230; <a title=\"Tim-3 Sustains Tumor Treg Stability and Function, Limiting Checkpoint Blockade Therapy Efficacy\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/15\/tim-3-sustains-tumor-treg-stability-and-function-limiting-checkpoint-blockade-therapy-efficacy\/\" aria-label=\"Read more about Tim-3 Sustains Tumor Treg Stability and Function, Limiting Checkpoint Blockade Therapy Efficacy\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/14\/a-patient-derived-screen-identifies-hdac-inhibitors-as-enhancers-of-phagocytosis-and-potent-immunotherapy-partners\/\">A Patient-Derived Screen Identifies HDAC Inhibitors as Enhancers of Phagocytosis and Potent Immunotherapy Partners<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-14T18:58:35+02:00\" class=\"wp-block-latest-posts__post-date\">14 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jul 14. doi: 10.1158\/2326-6066.CIR-25-0506. Online ahead of print. ABSTRACT Glioblastoma multiforme (GBM) is a lethal brain tumor with limited treatment options. Tumor-associated macrophages and microglia (TAMs) drive immune suppression and tumor progression, making them a key therapeutic target for GBM. Enhancing TAM phagocytosis in GBM has shown promise, particularly with innate &#8230; <a title=\"A Patient-Derived Screen Identifies HDAC Inhibitors as Enhancers of Phagocytosis and Potent Immunotherapy Partners\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/14\/a-patient-derived-screen-identifies-hdac-inhibitors-as-enhancers-of-phagocytosis-and-potent-immunotherapy-partners\/\" aria-label=\"Read more about A Patient-Derived Screen Identifies HDAC Inhibitors as Enhancers of Phagocytosis and Potent Immunotherapy Partners\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/10\/bet-inhibition-synergizes-with-rlr-signaling-to-enhance-tumor-immunogenicity-and-t-cell-recognition\/\">BET inhibition synergizes with RLR signaling to enhance tumor immunogenicity and T cell recognition<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-10T01:21:00+02:00\" class=\"wp-block-latest-posts__post-date\">10 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jul 9. doi: 10.1158\/2326-6066.CIR-25-0777. Online ahead of print. ABSTRACT Intratumoral signaling via the cytosolic double-stranded RNA (dsRNA) receptors RIG-I and MDA-5 enhance antitumor immunity and can overcome resistance to cancer immunotherapy. Although BET proteins are established epigenetic drivers of immune escape mechanisms, their role in regulating RIG-I-like receptor (RLR) signaling remains &#8230; <a title=\"BET inhibition synergizes with RLR signaling to enhance tumor immunogenicity and T cell recognition\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/10\/bet-inhibition-synergizes-with-rlr-signaling-to-enhance-tumor-immunogenicity-and-t-cell-recognition\/\" aria-label=\"Read more about BET inhibition synergizes with RLR signaling to enhance tumor immunogenicity and T cell recognition\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/09\/in-situ-vaccination-low-dose-targeted-radionuclide-therapy-and-immune-checkpoint-inhibition-eradicate-poorly-immunogenic-metastatic-tumors-in-murine-cancer-models\/\">In situ vaccination, low-dose targeted radionuclide therapy, and immune checkpoint inhibition eradicate poorly immunogenic metastatic tumors in murine cancer models<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-09T01:02:03+02:00\" class=\"wp-block-latest-posts__post-date\">9 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jul 8. doi: 10.1158\/2326-6066.CIR-25-1475. Online ahead of print. ABSTRACT Focal radiotherapy can provide an in situ vaccine (ISV) effect that may prime adaptive antitumor immunity, which can be augmented by combination with intratumoral immune adjuvants and systemic immune checkpoint inhibition. However, propagation of an antitumor immune response is not consistently achieved &#8230; <a title=\"In situ vaccination, low-dose targeted radionuclide therapy, and immune checkpoint inhibition eradicate poorly immunogenic metastatic tumors in murine cancer models\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/09\/in-situ-vaccination-low-dose-targeted-radionuclide-therapy-and-immune-checkpoint-inhibition-eradicate-poorly-immunogenic-metastatic-tumors-in-murine-cancer-models\/\" aria-label=\"Read more about In situ vaccination, low-dose targeted radionuclide therapy, and immune checkpoint inhibition eradicate poorly immunogenic metastatic tumors in murine cancer models\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/03\/car-t-cells-targeting-o-glycosylated-fibronectin-exhibit-potent-cytolytic-activity-and-combine-with-tumoral-toll-like-receptor-agonism-to-overcome-tumor-resistance\/\">CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-03T19:17:07+02:00\" class=\"wp-block-latest-posts__post-date\">3 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jul 3. doi: 10.1158\/2326-6066.CIR-26-0009. Online ahead of print. ABSTRACT Tumors remodel extracellular matrix (ECM) and glycosylation, yielding epitopes with restricted or limited detectability in normal adult tissues. Here, we evaluated the O-glycosylated IIICS domain of fibronectin (Tn-FN) as a chimeric antigen receptor (CAR) T cell target. FDC6-BB\u03b6 CAR T cells recognizing &#8230; <a title=\"CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/03\/car-t-cells-targeting-o-glycosylated-fibronectin-exhibit-potent-cytolytic-activity-and-combine-with-tumoral-toll-like-receptor-agonism-to-overcome-tumor-resistance\/\" aria-label=\"Read more about CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/03\/coordinated-immune-activation-following-kras-inhibition-in-syngeneic-models-reveals-molecular-pathways-that-potentiate-and-limit-antitumor-immunity\/\">Coordinated immune activation following KRAS inhibition in syngeneic models reveals molecular pathways that potentiate and limit antitumor immunity<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-03T19:17:07+02:00\" class=\"wp-block-latest-posts__post-date\">3 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jul 3. doi: 10.1158\/2326-6066.CIR-25-0794. Online ahead of print. ABSTRACT While mutant-specific KRAS inhibitors are approved to treat cancer, a deeper understanding of intratumoral changes driven specifically by KRAS inhibition is needed to maximize therapeutic responses. Here, we used single-cell RNA-seq, flow cytometry, and spatial transcriptomics to distinguish mechanisms of tumor control &#8230; <a title=\"Coordinated immune activation following KRAS inhibition in syngeneic models reveals molecular pathways that potentiate and limit antitumor immunity\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/03\/coordinated-immune-activation-following-kras-inhibition-in-syngeneic-models-reveals-molecular-pathways-that-potentiate-and-limit-antitumor-immunity\/\" aria-label=\"Read more about Coordinated immune activation following KRAS inhibition in syngeneic models reveals molecular pathways that potentiate and limit antitumor immunity\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/03\/enhancement-of-ferroptosis-in-escape-variant-tumor-cells-by-ifn-%ce%b3-derived-from-antigen-specific-t-cells-controls-tumor-with-heterogeneity\/\">Enhancement of ferroptosis in escape variant tumor cells by IFN-\u03b3 derived from antigen-specific T cells controls tumor with heterogeneity<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-03T19:17:06+02:00\" class=\"wp-block-latest-posts__post-date\">3 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jul 3. doi: 10.1158\/2326-6066.CIR-25-0175. Online ahead of print. ABSTRACT Tumor masses often exhibit heterogeneity, including escape variant clones that lack antigen-presenting machinery and\/or tumor antigens, which poses a major challenge to immunotherapy. Ferroptosis, a form of regulated cell death driven by iron-dependent lipid peroxidation, has been shown to effectively induce cell &#8230; <a title=\"Enhancement of ferroptosis in escape variant tumor cells by IFN-\u03b3 derived from antigen-specific T cells controls tumor with heterogeneity\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/03\/enhancement-of-ferroptosis-in-escape-variant-tumor-cells-by-ifn-%ce%b3-derived-from-antigen-specific-t-cells-controls-tumor-with-heterogeneity\/\" aria-label=\"Read more about Enhancement of ferroptosis in escape variant tumor cells by IFN-\u03b3 derived from antigen-specific T cells controls tumor with heterogeneity\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/02\/vista-neutrophils-contribute-to-platinum-resistance-by-suppressing-cd8t-cells-in-high-grade-serous-ovarian-cancer\/\">VISTA+ neutrophils contribute to platinum resistance by suppressing CD8+T cells in high-grade serous ovarian cancer<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-02T18:58:10+02:00\" class=\"wp-block-latest-posts__post-date\">2 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jul 2. doi: 10.1158\/2326-6066.CIR-25-1118. Online ahead of print. ABSTRACT Elevated neutrophil-to-lymphocyte ratio (NLR) has been associated with platinum resistance and poor outcomes in high-grade serous ovarian cancer (HGSOC), but the biological basis of this association remains unclear. We retrospectively analyzed 434 patients with HGSOC treated with platinum-based chemotherapy and found that &#8230; <a title=\"VISTA+ neutrophils contribute to platinum resistance by suppressing CD8+T cells in high-grade serous ovarian cancer\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/02\/vista-neutrophils-contribute-to-platinum-resistance-by-suppressing-cd8t-cells-in-high-grade-serous-ovarian-cancer\/\" aria-label=\"Read more about VISTA+ neutrophils contribute to platinum resistance by suppressing CD8+T cells in high-grade serous ovarian cancer\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/02\/a-sampling-of-highlights-from-the-literature-article-recommendations-from-our-deputy-and-senior-editors-14\/\">A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-02T12:54:44+02:00\" class=\"wp-block-latest-posts__post-date\">2 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jul 2;14(7):1051. doi: 10.1158\/2326-6066.CIR-14-7-WWR. NO ABSTRACT PMID:42388044 | DOI:10.1158\/2326-6066.CIR-14-7-WWR<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/30\/multinucleated-giant-cells-in-human-pancreatic-cancer-are-a-distinct-macrophage-population-undergoing-a-dna-damage-response-and-associated-with-an-aggressive-tumor-microenvironment\/\">Multinucleated giant cells in human pancreatic cancer are a distinct macrophage population undergoing a DNA damage response and associated with an aggressive tumor microenvironment<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-30T19:23:12+02:00\" class=\"wp-block-latest-posts__post-date\">30 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jun 30. doi: 10.1158\/2326-6066.CIR-25-1602. Online ahead of print. ABSTRACT Macrophages constitute a dominant and functionally diverse immune population within the microenvironment of pancreatic ductal adenocarcinoma (PDAC), yet how macrophage heterogeneity contributes to the tumor remains poorly defined. In an institutional cohort of 145 PDAC specimens, we identified a population of multinucleated &#8230; <a title=\"Multinucleated giant cells in human pancreatic cancer are a distinct macrophage population undergoing a DNA damage response and associated with an aggressive tumor microenvironment\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/30\/multinucleated-giant-cells-in-human-pancreatic-cancer-are-a-distinct-macrophage-population-undergoing-a-dna-damage-response-and-associated-with-an-aggressive-tumor-microenvironment\/\" aria-label=\"Read more about Multinucleated giant cells in human pancreatic cancer are a distinct macrophage population undergoing a DNA damage response and associated with an aggressive tumor microenvironment\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/29\/fueling-immunotherapy-resistance-ssbp4-links-tumor-cholesterol-biosynthesis-to-immune-evasion\/\">Fueling Immunotherapy Resistance: SSBP4 Links Tumor Cholesterol Biosynthesis to Immune Evasion<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-29T18:56:06+02:00\" class=\"wp-block-latest-posts__post-date\">29 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jun 29:OF1-OF2. doi: 10.1158\/2326-6066.CIR-26-0635. Online ahead of print. ABSTRACT Immune checkpoint inhibitors (ICI) have had a transformative impact on cancer treatment. However, many patients still fail to respond to ICIs, underscoring the need to identify novel drivers of resistance. In this issue, Ou and colleagues identify single-stranded DNA binding protein 4 &#8230; <a title=\"Fueling Immunotherapy Resistance: SSBP4 Links Tumor Cholesterol Biosynthesis to Immune Evasion\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/29\/fueling-immunotherapy-resistance-ssbp4-links-tumor-cholesterol-biosynthesis-to-immune-evasion\/\" aria-label=\"Read more about Fueling Immunotherapy Resistance: SSBP4 Links Tumor Cholesterol Biosynthesis to Immune Evasion\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/27\/peripheral-th17-immune-signature-associates-with-excellent-response-to-anti-pd1-anti-pd-l1-therapy-across-solid-tumors\/\">Peripheral Th17 immune signature associates with excellent response to anti-PD1\/anti-PD-L1 therapy across solid tumors<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-27T07:45:48+02:00\" class=\"wp-block-latest-posts__post-date\">27 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jun 26. doi: 10.1158\/2326-6066.CIR-25-1611. Online ahead of print. ABSTRACT Immune checkpoint inhibitors (ICIs) have transformed cancer care, at times generating durable partial or even complete responses in advanced cancers. However, only a minority of patients experience these &#8220;excellent&#8221; responses. Thus, there is a need for novel biomarkers that can identify those &#8230; <a title=\"Peripheral Th17 immune signature associates with excellent response to anti-PD1\/anti-PD-L1 therapy across solid tumors\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/27\/peripheral-th17-immune-signature-associates-with-excellent-response-to-anti-pd1-anti-pd-l1-therapy-across-solid-tumors\/\" aria-label=\"Read more about Peripheral Th17 immune signature associates with excellent response to anti-PD1\/anti-PD-L1 therapy across solid tumors\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/23\/cancer-intrinsic-protein-neddylation-modulates-the-intra-tumoral-immune-landscape-to-constrain-immune-checkpoint-blockade-therapy\/\">Cancer intrinsic protein neddylation modulates the intra-tumoral immune landscape to constrain immune checkpoint blockade therapy<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-23T01:49:49+02:00\" class=\"wp-block-latest-posts__post-date\">23 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jun 22. doi: 10.1158\/2326-6066.CIR-25-1309. Online ahead of print. ABSTRACT The cancer intrinsic network controlling response to immune checkpoint blockade therapy remains elusive. Using a published single-cell RNA sequencing (scRNA-seq) dataset from breast cancer patients, we found that pre-therapy mRNA expression of NEDD8, which encodes the regulatory protein essential for neddylation, in &#8230; <a title=\"Cancer intrinsic protein neddylation modulates the intra-tumoral immune landscape to constrain immune checkpoint blockade therapy\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/23\/cancer-intrinsic-protein-neddylation-modulates-the-intra-tumoral-immune-landscape-to-constrain-immune-checkpoint-blockade-therapy\/\" aria-label=\"Read more about Cancer intrinsic protein neddylation modulates the intra-tumoral immune landscape to constrain immune checkpoint blockade therapy\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/18\/adar1-deficiency-in-pancreatic-cancer-cells-potentiates-cdc1-activation-and-promotes-sensitization-to-immunotherapy\/\">ADAR1 deficiency in pancreatic cancer cells potentiates cDC1 activation and promotes sensitization to immunotherapy<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-18T01:26:31+02:00\" class=\"wp-block-latest-posts__post-date\">18 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jun 17. doi: 10.1158\/2326-6066.CIR-25-1626. Online ahead of print. ABSTRACT Pancreatic cancer responds poorly to immunotherapy, primarily due to poor activation of CD8+ T cells and their limited infiltration into the tumor tissue. Strategies to enhance CD8+ T-cell priming and function are therefore critical for improving immunotherapeutic efficacy in pancreatic cancer. The &#8230; <a title=\"ADAR1 deficiency in pancreatic cancer cells potentiates cDC1 activation and promotes sensitization to immunotherapy\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/18\/adar1-deficiency-in-pancreatic-cancer-cells-potentiates-cdc1-activation-and-promotes-sensitization-to-immunotherapy\/\" aria-label=\"Read more about ADAR1 deficiency in pancreatic cancer cells potentiates cDC1 activation and promotes sensitization to immunotherapy\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/12\/dna-hypomethylating-agents-preserve-t-cell-stemness-and-potentiate-the-efficacy-of-cd3-bispecific-antibodies\/\">DNA hypomethylating agents preserve T cell stemness and potentiate the efficacy of CD3-bispecific antibodies<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-12T01:17:35+02:00\" class=\"wp-block-latest-posts__post-date\">12 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jun 11. doi: 10.1158\/2326-6066.CIR-25-1420. Online ahead of print. ABSTRACT Bispecific antibodies targeting tumor-associated antigens and CD3 are promising therapeutic agents for both solid and hematologic cancers. CD3-bispecifics induce T cell activation and cytotoxicity; however, prolonged TCR stimulation can lead to chromatin rewiring and T cell dysfunction, thereby limiting their full therapeutic &#8230; <a title=\"DNA hypomethylating agents preserve T cell stemness and potentiate the efficacy of CD3-bispecific antibodies\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/12\/dna-hypomethylating-agents-preserve-t-cell-stemness-and-potentiate-the-efficacy-of-cd3-bispecific-antibodies\/\" aria-label=\"Read more about DNA hypomethylating agents preserve T cell stemness and potentiate the efficacy of CD3-bispecific antibodies\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/12\/topical-resiquimod-elicits-systemic-protection-and-improves-anti-pd1-therapy-in-melanoma-via-priming-of-cd8-t-cells\/\">Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-12T01:17:35+02:00\" class=\"wp-block-latest-posts__post-date\">12 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jun 11. doi: 10.1158\/2326-6066.CIR-25-0998. Online ahead of print. ABSTRACT The Toll-like receptor (TLR) 7\/8 agonist resiquimod shows promise for treating cutaneous T cell lymphoma and actinic keratosis, yet its mechanism of action remains unclear. We demonstrated that topical resiquimod significantly inhibited melanoma growth across various genetic and syngeneic mouse models, prolonged &#8230; <a title=\"Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/12\/topical-resiquimod-elicits-systemic-protection-and-improves-anti-pd1-therapy-in-melanoma-via-priming-of-cd8-t-cells\/\" aria-label=\"Read more about Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/11\/multiple-myeloma-cells-resistant-to-t-cell-therapies-exhibits-a-cd45-immune-evasive-phenotype\/\">Multiple Myeloma Cells Resistant to T-cell Therapies Exhibits a CD45+ Immune Evasive Phenotype<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-11T12:00:48+02:00\" class=\"wp-block-latest-posts__post-date\">11 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jun 10. doi: 10.1158\/2326-6066.CIR-25-1068. Online ahead of print. ABSTRACT Multiple myeloma (MM) is plasma cell malignancy that is mostly incurable, even with recent advances in treatment such as BCMA-targeted chimeric antigen receptor (CAR) T cells and bispecific T cell-engaging antibodies (TCEs). To better understand this treatment resistance, we examined MM cells &#8230; <a title=\"Multiple Myeloma Cells Resistant to T-cell Therapies Exhibits a CD45+ Immune Evasive Phenotype\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/11\/multiple-myeloma-cells-resistant-to-t-cell-therapies-exhibits-a-cd45-immune-evasive-phenotype\/\" aria-label=\"Read more about Multiple Myeloma Cells Resistant to T-cell Therapies Exhibits a CD45+ Immune Evasive Phenotype\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/09\/cancer-chemo-immunotherapy-time-will-tell\/\">Cancer chemo-immunotherapy: time will tell<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-09T01:49:30+02:00\" class=\"wp-block-latest-posts__post-date\">9 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jun 8. doi: 10.1158\/2326-6066.CIR-26-0335. Online ahead of print. ABSTRACT Endogenous circadian programs coordinate physiology across tissues, including immune cell trafficking and drug metabolism. Previous retrospective studies suggested that the timing of immune checkpoint inhibitor delivery may be a modifiable determinant of survival in patients with cancer, with earlier infusions often associated &#8230; <a title=\"Cancer chemo-immunotherapy: time will tell\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/09\/cancer-chemo-immunotherapy-time-will-tell\/\" aria-label=\"Read more about Cancer chemo-immunotherapy: time will tell\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/09\/ilt2-identifies-an-unexploited-pool-of-intratumoral-cd8-bystander-t-cells-with-tcr-independent-cytotoxicity-in-renal-cell-carcinoma\/\">ILT2 identifies an unexploited pool of intratumoral CD8+ bystander T cells with TCR-independent cytotoxicity in renal cell carcinoma<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-09T01:49:30+02:00\" class=\"wp-block-latest-posts__post-date\">9 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jun 8. doi: 10.1158\/2326-6066.CIR-25-1109. Online ahead of print. ABSTRACT Immune checkpoint inhibitors (ICIs) have improved clear-cell renal cell carcinoma (ccRCC) therapy, yet many patients remain unresponsive. Alternative strategies are needed, and the HLA-G\/ILT2 axis has emerged as a promising immunosuppressive pathway. Here, we deeply characterized CD8\u207aILT2\u207a tumor-infiltrating lymphocytes (TILs) as a &#8230; <a title=\"ILT2 identifies an unexploited pool of intratumoral CD8+ bystander T cells with TCR-independent cytotoxicity in renal cell carcinoma\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/09\/ilt2-identifies-an-unexploited-pool-of-intratumoral-cd8-bystander-t-cells-with-tcr-independent-cytotoxicity-in-renal-cell-carcinoma\/\" aria-label=\"Read more about ILT2 identifies an unexploited pool of intratumoral CD8+ bystander T cells with TCR-independent cytotoxicity in renal cell carcinoma\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/02\/a-sampling-of-highlights-from-the-literature-article-recommendations-from-our-deputy-and-senior-editors-13\/\">A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-02T13:24:44+02:00\" class=\"wp-block-latest-posts__post-date\">2 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jun 2;14(6):899. doi: 10.1158\/2326-6066.CIR-14-6-WWR. NO ABSTRACT PMID:42226639 | DOI:10.1158\/2326-6066.CIR-14-6-WWR<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/29\/targeting-ccr1-remodels-the-tumor-microenvironment-and-relieves-immune-suppression-in-pancreatic-cancer\/\">Targeting CCR1 remodels the tumor microenvironment and relieves immune suppression in pancreatic cancer<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-05-29T22:08:27+02:00\" class=\"wp-block-latest-posts__post-date\">29 de May de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 May 28. doi: 10.1158\/2326-6066.CIR-25-1300. Online ahead of print. ABSTRACT A hallmark of pancreatic cancer is an extensive fibroinflammatory stroma. Myeloid cells, including abundant macrophages, are a prevalent cellular component of the pancreatic cancer microenvironment and a key driver of immunosuppression. Identifying mechanisms of myeloid-cell driven immunosuppression is thus key to developing &#8230; <a title=\"Targeting CCR1 remodels the tumor microenvironment and relieves immune suppression in pancreatic cancer\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/29\/targeting-ccr1-remodels-the-tumor-microenvironment-and-relieves-immune-suppression-in-pancreatic-cancer\/\" aria-label=\"Read more about Targeting CCR1 remodels the tumor microenvironment and relieves immune suppression in pancreatic cancer\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/21\/help-male-hormones-dampen-cd4-t-cell-help-in-cancer\/\">Help! Male Hormones Dampen CD4+ T-cell Help in Cancer<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-05-21T19:04:32+02:00\" class=\"wp-block-latest-posts__post-date\">21 de May de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 May 21:OF1-OF2. doi: 10.1158\/2326-6066.CIR-26-0513. Online ahead of print. ABSTRACT Sex differences in antitumor immunity contribute to disparities in cancer outcomes, yet the role of CD4+ T helper cells in this context remains poorly understood. In this issue, Hunt and colleagues show that sex hormones restrain CD4+ T-cell help in males, weakening &#8230; <a title=\"Help! Male Hormones Dampen CD4+ T-cell Help in Cancer\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/21\/help-male-hormones-dampen-cd4-t-cell-help-in-cancer\/\" aria-label=\"Read more about Help! Male Hormones Dampen CD4+ T-cell Help in Cancer\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/16\/reprogramming-car-with-cytokine-signaling-increases-the-efficacy-of-car-t-cell-therapy-in-solid-tumour-treatment-and-confers-sustained-immune-memory\/\">Reprogramming CAR with cytokine signaling increases the efficacy of CAR-T cell therapy in solid tumour treatment and confers sustained immune memory<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-05-16T00:46:38+02:00\" class=\"wp-block-latest-posts__post-date\">16 de May de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 May 15. doi: 10.1158\/2326-6066.CIR-25-1490. Online ahead of print. ABSTRACT Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable efficacy in hematologic malignancies but remains limited in solid tumors because of the immunosuppressive microenvironment, tumor heterogeneity, poor immune-cell infiltration, and progressive T-cell dysfunction. Because cytokine costimulation is critical for maintaining T-cell fitness, &#8230; <a title=\"Reprogramming CAR with cytokine signaling increases the efficacy of CAR-T cell therapy in solid tumour treatment and confers sustained immune memory\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/16\/reprogramming-car-with-cytokine-signaling-increases-the-efficacy-of-car-t-cell-therapy-in-solid-tumour-treatment-and-confers-sustained-immune-memory\/\" aria-label=\"Read more about Reprogramming CAR with cytokine signaling increases the efficacy of CAR-T cell therapy in solid tumour treatment and confers sustained immune memory\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/14\/hypoxia-induced-adam8%e2%81%ba-macrophages-and-fap%e2%81%ba-fibroblasts-form-an-extracellular-matrix-remodeling-niche-at-the-tumor-boundary-in-hcc\/\">Hypoxia-induced ADAM8\u207a macrophages and FAP\u207a fibroblasts form an extracellular matrix-remodeling niche at the tumor boundary in HCC<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-05-14T00:53:06+02:00\" class=\"wp-block-latest-posts__post-date\">14 de May de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 May 13. doi: 10.1158\/2326-6066.CIR-25-1240. Online ahead of print. ABSTRACT In hepatocellular carcinoma (HCC), stromal and immune components shape invasion and metastasis. To identify the cellular states that drive extracellular matrix (ECM) remodeling, define their organization at the tumor margin, and evaluate their association with prognosis, we profiled stromal regions at the &#8230; <a title=\"Hypoxia-induced ADAM8\u207a macrophages and FAP\u207a fibroblasts form an extracellular matrix-remodeling niche at the tumor boundary in HCC\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/14\/hypoxia-induced-adam8%e2%81%ba-macrophages-and-fap%e2%81%ba-fibroblasts-form-an-extracellular-matrix-remodeling-niche-at-the-tumor-boundary-in-hcc\/\" aria-label=\"Read more about Hypoxia-induced ADAM8\u207a macrophages and FAP\u207a fibroblasts form an extracellular matrix-remodeling niche at the tumor boundary in HCC\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/11\/low-strength-type-i-interferon-signaling-promotes-car-t-cell-treatment-efficacy\/\">Low-Strength Type I Interferon Signaling Promotes CAR T Cell Treatment Efficacy<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-05-11T19:47:26+02:00\" class=\"wp-block-latest-posts__post-date\">11 de May de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 May 11. doi: 10.1158\/2326-6066.CIR-25-0691. Online ahead of print. ABSTRACT CD19-directed chimeric antigen receptor (CAR) T-cell therapy has significantly advanced the treatment landscape for relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL). However, up to 60% of patients do not achieve a complete response. To uncover determinants of therapeutic efficacy, we analyzed the &#8230; <a title=\"Low-Strength Type I Interferon Signaling Promotes CAR T Cell Treatment Efficacy\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/11\/low-strength-type-i-interferon-signaling-promotes-car-t-cell-treatment-efficacy\/\" aria-label=\"Read more about Low-Strength Type I Interferon Signaling Promotes CAR T Cell Treatment Efficacy\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/06\/automated-computational-flow-cytometry-correlates-decreasing-neutrophil-to-lymphocyte-ratio-to-improved-survival-in-nsclc-after-immune-checkpoint-blockade\/\">Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC After Immune Checkpoint Blockade<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-05-06T18:44:20+02:00\" class=\"wp-block-latest-posts__post-date\">6 de May de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 May 6. doi: 10.1158\/2326-6066.CIR-25-0662. Online ahead of print. ABSTRACT Immune checkpoint blockade (ICB) therapy is transforming non-small cell lung cancer (NSCLC) treatment and prolonging overall survival (OS). However, not all patients are responsive. Using computational cytometry analysis to identify immune cell subsets and early dynamic changes, we aimed to unravel the &#8230; <a title=\"Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC After Immune Checkpoint Blockade\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/06\/automated-computational-flow-cytometry-correlates-decreasing-neutrophil-to-lymphocyte-ratio-to-improved-survival-in-nsclc-after-immune-checkpoint-blockade\/\" aria-label=\"Read more about Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC After Immune Checkpoint Blockade\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/06\/uba2-high-osteosarcoma-suppresses-immune-infiltration-by-autophagy-mediated-mhc-i-degradation\/\">UBA2-High Osteosarcoma Suppresses Immune Infiltration by Autophagy-Mediated MHC-I Degradation<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-05-06T01:22:49+02:00\" class=\"wp-block-latest-posts__post-date\">6 de May de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 May 5. doi: 10.1158\/2326-6066.CIR-25-1321. Online ahead of print. ABSTRACT Osteosarcoma (OS) responds poorly to immune-checkpoint blockade (ICB), and the molecular drivers of its immune-cold state remain unclear. Using multi-omics analyses, we identified an immune-cold OS subtype characterized by enrichment of protein SUMOylation and found the SUMO E1 subunit UBA2 as a &#8230; <a title=\"UBA2-High Osteosarcoma Suppresses Immune Infiltration by Autophagy-Mediated MHC-I Degradation\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/06\/uba2-high-osteosarcoma-suppresses-immune-infiltration-by-autophagy-mediated-mhc-i-degradation\/\" aria-label=\"Read more about UBA2-High Osteosarcoma Suppresses Immune Infiltration by Autophagy-Mediated MHC-I Degradation\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/04\/a-sampling-of-highlights-from-the-literature-article-recommendations-from-our-deputy-and-senior-editors-12\/\">A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-05-04T12:41:35+02:00\" class=\"wp-block-latest-posts__post-date\">4 de May de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 May 4;14(5):715. doi: 10.1158\/2326-6066.CIR-14-5-WWR. NO ABSTRACT PMID:42076931 | DOI:10.1158\/2326-6066.CIR-14-5-WWR<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/30\/cancer-cell-intrinsic-ssbp4-enables-tumor-immune-evasion-by-promoting-cholesterol-biosynthesis\/\">Cancer cell-intrinsic SSBP4 enables tumor immune evasion by promoting cholesterol biosynthesis<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-30T00:54:07+02:00\" class=\"wp-block-latest-posts__post-date\">30 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Apr 29. doi: 10.1158\/2326-6066.CIR-25-1312. Online ahead of print. ABSTRACT The immunosuppressive tumor microenvironment (TME) contributes to resistance against checkpoint inhibitors. However, the precise factors that shape the immune contexture of the TME remain elusive. Here, we report that Single-Stranded DNA Binding Protein 4 (SSBP4), a previously uncharacterized protein, suppresses intratumoral T-cell &#8230; <a title=\"Cancer cell-intrinsic SSBP4 enables tumor immune evasion by promoting cholesterol biosynthesis\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/30\/cancer-cell-intrinsic-ssbp4-enables-tumor-immune-evasion-by-promoting-cholesterol-biosynthesis\/\" aria-label=\"Read more about Cancer cell-intrinsic SSBP4 enables tumor immune evasion by promoting cholesterol biosynthesis\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/29\/tumor-derived-complement-c3-overexpression-in-stk11-mutant-lung-adenocarcinoma-drives-tumor-growth-and-immune-checkpoint-inhibitor-resistance\/\">Tumor-derived complement C3 overexpression in STK11-mutant lung adenocarcinoma drives tumor growth and immune checkpoint inhibitor resistance<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-29T00:31:19+02:00\" class=\"wp-block-latest-posts__post-date\">29 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Apr 28. doi: 10.1158\/2326-6066.CIR-25-0534. Online ahead of print. ABSTRACT Loss-of-function STK11 mutations occur in 15-20% of lung adenocarcinomas (LUAD) and correlate with immunotherapy failure and worse survival. By integrating analysis of human tumor samples, a human LUAD cell line panel, and CCLE and TCGA datasets, we found that C3 production was &#8230; <a title=\"Tumor-derived complement C3 overexpression in STK11-mutant lung adenocarcinoma drives tumor growth and immune checkpoint inhibitor resistance\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/29\/tumor-derived-complement-c3-overexpression-in-stk11-mutant-lung-adenocarcinoma-drives-tumor-growth-and-immune-checkpoint-inhibitor-resistance\/\" aria-label=\"Read more about Tumor-derived complement C3 overexpression in STK11-mutant lung adenocarcinoma drives tumor growth and immune checkpoint inhibitor resistance\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/28\/lenvatinib-combined-with-pd-1-blockade-therapy-benefits-gastric-cancers-through-immunosuppressive-macrophage-modulation\/\">Lenvatinib combined with PD-1 blockade therapy benefits gastric cancers through immunosuppressive macrophage modulation<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-28T01:12:26+02:00\" class=\"wp-block-latest-posts__post-date\">28 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Apr 27. doi: 10.1158\/2326-6066.CIR-25-0982. Online ahead of print. ABSTRACT The combination of multikinase inhibitors with PD-1 blockade therapy has emerged as a promising strategy to overcome resistance to PD-1 blockade monotherapy across multiple cancer types, including gastric cancer (GC). Here, we report that the multikinase inhibitor lenvatinib selectively reduced the number &#8230; <a title=\"Lenvatinib combined with PD-1 blockade therapy benefits gastric cancers through immunosuppressive macrophage modulation\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/28\/lenvatinib-combined-with-pd-1-blockade-therapy-benefits-gastric-cancers-through-immunosuppressive-macrophage-modulation\/\" aria-label=\"Read more about Lenvatinib combined with PD-1 blockade therapy benefits gastric cancers through immunosuppressive macrophage modulation\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/27\/an-icam1-targeting-chimeric-costimulatory-receptor-mimics-the-immune-synapse-and-enhances-tumor-specific-t-cell-function\/\">An ICAM1-targeting chimeric costimulatory receptor mimics the immune synapse and enhances tumor-specific T cell function<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-27T19:06:20+02:00\" class=\"wp-block-latest-posts__post-date\">27 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Apr 27. doi: 10.1158\/2326-6066.CIR-25-0529. Online ahead of print. ABSTRACT Engineered T cell therapies, such as chimeric antigen receptor (CAR) and T cell receptor (TCR)-based approaches, have transformed outcomes in hematological malignancies, yet their efficacy in solid tumors remains limited by tumor antigen escape, immunosuppressive microenvironments, and insufficient activation of CAR or &#8230; <a title=\"An ICAM1-targeting chimeric costimulatory receptor mimics the immune synapse and enhances tumor-specific T cell function\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/27\/an-icam1-targeting-chimeric-costimulatory-receptor-mimics-the-immune-synapse-and-enhances-tumor-specific-t-cell-function\/\" aria-label=\"Read more about An ICAM1-targeting chimeric costimulatory receptor mimics the immune synapse and enhances tumor-specific T cell function\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/24\/nmb-cxcl13-cd4-t-cells-derived-neuromedin-b-promotes-neuropeptide-s-receptor-1-positive-malignant-cells-senescence-and-malignancy\/\">NMB+ CXCL13+ CD4+ T cells -derived neuromedin-B promotes neuropeptide S receptor 1 positive malignant cells senescence and malignancy<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-24T19:01:28+02:00\" class=\"wp-block-latest-posts__post-date\">24 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Apr 24. doi: 10.1158\/2326-6066.CIR-25-1081. Online ahead of print. ABSTRACT Colorectal cancer (CRC) with liver metastases (CRCLM) remains a clinical challenge. CXCL13 is widely recognized as a biomarker of immunotherapy response. However, the functional heterogeneity (protumor vs. antitumor) of CXCL13\u207aCD4\u207a T cell subsets has long been controversial. Through integrated analysis of single-cell &#8230; <a title=\"NMB+ CXCL13+ CD4+ T cells -derived neuromedin-B promotes neuropeptide S receptor 1 positive malignant cells senescence and malignancy\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/24\/nmb-cxcl13-cd4-t-cells-derived-neuromedin-b-promotes-neuropeptide-s-receptor-1-positive-malignant-cells-senescence-and-malignancy\/\" aria-label=\"Read more about NMB+ CXCL13+ CD4+ T cells -derived neuromedin-B promotes neuropeptide S receptor 1 positive malignant cells senescence and malignancy\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/23\/low-inflammation-correlates-with-protumor-tim4trem1-resident-macrophage-expansion-and-limited-monocyte-derived-macrophage-differentiation-during-peritoneal-colorectal-cancer\/\">Low inflammation correlates with protumor Tim4+TREM1+ resident macrophage expansion and limited monocyte-derived macrophage differentiation during peritoneal colorectal cancer<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-23T19:38:00+02:00\" class=\"wp-block-latest-posts__post-date\">23 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Apr 23. doi: 10.1158\/2326-6066.CIR-25-0388. Online ahead of print. ABSTRACT Accumulating evidence indicates that peritoneal macrophages, comprising resident peritoneal macrophages (resM\u00d8s) and monocyte-derived non-resident macrophages (moM\u00d8s), contribute to peritoneal tumor progression, by promoting tumor cell proliferation and migration, and driving immunosuppression. However, the mechanisms governing the expansion of resM\u00d8s and moM\u00d8s, as &#8230; <a title=\"Low inflammation correlates with protumor Tim4+TREM1+ resident macrophage expansion and limited monocyte-derived macrophage differentiation during peritoneal colorectal cancer\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/23\/low-inflammation-correlates-with-protumor-tim4trem1-resident-macrophage-expansion-and-limited-monocyte-derived-macrophage-differentiation-during-peritoneal-colorectal-cancer\/\" aria-label=\"Read more about Low inflammation correlates with protumor Tim4+TREM1+ resident macrophage expansion and limited monocyte-derived macrophage differentiation during peritoneal colorectal cancer\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/22\/targeted-tnf-potentiates-the-activity-of-bispecific-t-cell-engagers-in-solid-tumors-by-turning-cold-tumors-hot\/\">Targeted TNF Potentiates the Activity of Bispecific T-cell Engagers in Solid Tumors by Turning Cold Tumors Hot<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-22T00:51:13+02:00\" class=\"wp-block-latest-posts__post-date\">22 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Apr 21:OF1-OF14. doi: 10.1158\/2326-6066.CIR-25-1572. Online ahead of print. ABSTRACT Colorectal cancer remains a major global health burden and an area of urgent unmet medical need. Immunotherapy has shown limited success in colorectal cancer as most patients present with an immune-excluded, &#8220;cold&#8221; tumor microenvironment (TME). In this study, we report a dual-modality &#8230; <a title=\"Targeted TNF Potentiates the Activity of Bispecific T-cell Engagers in Solid Tumors by Turning Cold Tumors Hot\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/22\/targeted-tnf-potentiates-the-activity-of-bispecific-t-cell-engagers-in-solid-tumors-by-turning-cold-tumors-hot\/\" aria-label=\"Read more about Targeted TNF Potentiates the Activity of Bispecific T-cell Engagers in Solid Tumors by Turning Cold Tumors Hot\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/21\/a-sampling-of-highlights-from-the-literature-8\/\">A Sampling of Highlights from the Literature<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-21T19:46:28+02:00\" class=\"wp-block-latest-posts__post-date\">21 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2024 Nov 4;12(11):1491. doi: 10.1158\/2326-6066.CIR-12-11-WWR. NO ABSTRACT PMID:42008778 | DOI:10.1158\/2326-6066.CIR-12-11-WWR<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/21\/a-sampling-of-highlights-from-the-literature-9\/\">A Sampling of Highlights from the Literature<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-21T19:46:28+02:00\" class=\"wp-block-latest-posts__post-date\">21 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2025 May 2;13(5):617. doi: 10.1158\/2326-6066.CIR-13-5-WWR. NO ABSTRACT PMID:42008760 | DOI:10.1158\/2326-6066.CIR-13-5-WWR<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/13\/atf7ip-inhibits-the-tumor-immune-response-by-promoting-terminal-cd8-t-cell-exhaustion\/\">ATF7ip inhibits the tumor immune response by promoting terminal CD8+ T cell Exhaustion<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-13T19:10:08+02:00\" class=\"wp-block-latest-posts__post-date\">13 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Apr 13. doi: 10.1158\/2326-6066.CIR-25-0816. Online ahead of print. ABSTRACT CD8+ T cell exhaustion limits the immune response to tumors because of ineffective T cell effector functions. Thus, therapies that inhibit T-cell exhaustion are critical for optimizing cancer treatment. Recent studies have implicated epigenetic proteins in T-cell exhaustion. Here, we identified activating &#8230; <a title=\"ATF7ip inhibits the tumor immune response by promoting terminal CD8+ T cell Exhaustion\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/13\/atf7ip-inhibits-the-tumor-immune-response-by-promoting-terminal-cd8-t-cell-exhaustion\/\" aria-label=\"Read more about ATF7ip inhibits the tumor immune response by promoting terminal CD8+ T cell Exhaustion\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/11\/ddr1-promotes-immune-evasion-in-colorectal-cancer-by-orchestrating-il-33-mediated-m2-like-polarization-of-tumor-associated-macrophages\/\">DDR1 Promotes Immune Evasion in Colorectal Cancer by Orchestrating IL-33-Mediated M2-like Polarization of Tumor-Associated Macrophages<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-11T01:08:58+02:00\" class=\"wp-block-latest-posts__post-date\">11 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Apr 10. doi: 10.1158\/2326-6066.CIR-25-1073. Online ahead of print. ABSTRACT Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with low immunotherapy efficacy due to an immunosuppressive tumor microenvironment in proficient mismatch repair (pMMR) disease, which accounts for most cases of CRC. Herine, we have identified discoidin domain receptor 1 (DDR1) &#8230; <a title=\"DDR1 Promotes Immune Evasion in Colorectal Cancer by Orchestrating IL-33-Mediated M2-like Polarization of Tumor-Associated Macrophages\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/11\/ddr1-promotes-immune-evasion-in-colorectal-cancer-by-orchestrating-il-33-mediated-m2-like-polarization-of-tumor-associated-macrophages\/\" aria-label=\"Read more about DDR1 Promotes Immune Evasion in Colorectal Cancer by Orchestrating IL-33-Mediated M2-like Polarization of Tumor-Associated Macrophages\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/11\/tumor-infiltrating-platelets-recruit-neutrophils-to-promote-tumor-growth-through-the-5-hiaa-gpr35-erk1-2-axis-in-hepatocellular-carcinoma\/\">Tumor-infiltrating platelets recruit neutrophils to promote tumor growth through the 5-HIAA-GPR35-ERK1\/2 axis in Hepatocellular Carcinoma<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-11T01:08:58+02:00\" class=\"wp-block-latest-posts__post-date\">11 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Apr 10. doi: 10.1158\/2326-6066.CIR-25-0498. Online ahead of print. ABSTRACT Tumor-associated neutrophils (TANs) promote tumor growth and metastasis in hepatocellular carcinoma (HCC). Platelets can activate neutrophils and contribute to inflammation and organ damage; however, the relationship between TANs and platelets in HCC remains unclear. We performed multiplex immunohistochemistry and found that tumor-infiltrating &#8230; <a title=\"Tumor-infiltrating platelets recruit neutrophils to promote tumor growth through the 5-HIAA-GPR35-ERK1\/2 axis in Hepatocellular Carcinoma\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/11\/tumor-infiltrating-platelets-recruit-neutrophils-to-promote-tumor-growth-through-the-5-hiaa-gpr35-erk1-2-axis-in-hepatocellular-carcinoma\/\" aria-label=\"Read more about Tumor-infiltrating platelets recruit neutrophils to promote tumor growth through the 5-HIAA-GPR35-ERK1\/2 axis in Hepatocellular Carcinoma\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/02\/a-sampling-of-highlights-from-the-literature-article-recommendations-from-our-deputy-and-senior-editors-11\/\">A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-02T12:42:02+02:00\" class=\"wp-block-latest-posts__post-date\">2 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Apr 2;14(4):527. doi: 10.1158\/2326-6066.CIR-14-4-WWR. NO ABSTRACT PMID:41923516 | DOI:10.1158\/2326-6066.CIR-14-4-WWR<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/31\/b-cells-and-tertiary-lymphoid-structures-as-integral-components-of-the-cancer-immunity-cycle\/\">B Cells and Tertiary Lymphoid Structures as Integral Components of the Cancer Immunity Cycle<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-31T18:42:35+02:00\" class=\"wp-block-latest-posts__post-date\">31 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Mar 31:OF1-OF2. doi: 10.1158\/2326-6066.CIR-26-0311. Online ahead of print. ABSTRACT The influence B cells have in the tumor microenvironment has historically remained unresolved across solid tumors. At the same time, numerous findings of ectopic germinal centers in inflamed tumors containing tertiary lymphoid structures have been the impetus for redefining what effective antitumor &#8230; <a title=\"B Cells and Tertiary Lymphoid Structures as Integral Components of the Cancer Immunity Cycle\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/31\/b-cells-and-tertiary-lymphoid-structures-as-integral-components-of-the-cancer-immunity-cycle\/\" aria-label=\"Read more about B Cells and Tertiary Lymphoid Structures as Integral Components of the Cancer Immunity Cycle\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/31\/induction-serplulimab-and-chemotherapy-followed-by-chemoradiotherapy-for-bulky-unresectable-stage-iii-nsclc-a-phase-ii-study-succeed-01\/\">Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-31T01:28:53+02:00\" class=\"wp-block-latest-posts__post-date\">31 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Mar 30. doi: 10.1158\/2326-6066.CIR-25-1194. Online ahead of print. ABSTRACT Patients with bulky, unresectable stage III non-small cell lung cancer (NSCLC) face poor outcomes with standard concurrent chemoradiotherapy (cCRT) due to large radiation fields and toxicity risks. We evaluated the feasibility and efficacy of induction immunochemotherapy to downstage tumors prior to cCRT. &#8230; <a title=\"Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/31\/induction-serplulimab-and-chemotherapy-followed-by-chemoradiotherapy-for-bulky-unresectable-stage-iii-nsclc-a-phase-ii-study-succeed-01\/\" aria-label=\"Read more about Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/26\/reduced-tumor-control-in-males-can-result-from-impaired-cd4-t-cell-help-through-the-cd40l-cd40-pathway\/\">Reduced tumor control in males can result from impaired CD4+ T-cell help through the CD40L-CD40 pathway<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-26T00:59:22+01:00\" class=\"wp-block-latest-posts__post-date\">26 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Mar 25. doi: 10.1158\/2326-6066.CIR-25-1115. Online ahead of print. ABSTRACT Sex-based differences in cancer incidence are incompletely understood, but potential roles for the immune system are beginning to emerge. CD4+ T cells play a central role in coordinating antitumor immunity. In addition to cytokine production, CD40L expression on CD4+ T cells provides &#8230; <a title=\"Reduced tumor control in males can result from impaired CD4+ T-cell help through the CD40L-CD40 pathway\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/26\/reduced-tumor-control-in-males-can-result-from-impaired-cd4-t-cell-help-through-the-cd40l-cd40-pathway\/\" aria-label=\"Read more about Reduced tumor control in males can result from impaired CD4+ T-cell help through the CD40L-CD40 pathway\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/21\/co-expression-of-il15-promotes-effector-differentiation-and-sustained-proliferative-capacity-in-alppl2-specific-human-car-t-cells\/\">Co-expression of IL15 promotes effector differentiation and sustained proliferative capacity in ALPPL2-specific human CAR T cells<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-21T00:05:57+01:00\" class=\"wp-block-latest-posts__post-date\">21 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Mar 20. doi: 10.1158\/2326-6066.CIR-25-0609. Online ahead of print. ABSTRACT Chimeric antigen receptor (CAR) T cells have robust antitumor activity against hematologic malignancies and have the potential to benefit patients with solid tumors. Immune recognition of murine proteins expressed in adoptively transferred T cells and lack of homeostatic cytokines in the tumor &#8230; <a title=\"Co-expression of IL15 promotes effector differentiation and sustained proliferative capacity in ALPPL2-specific human CAR T cells\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/21\/co-expression-of-il15-promotes-effector-differentiation-and-sustained-proliferative-capacity-in-alppl2-specific-human-car-t-cells\/\" aria-label=\"Read more about Co-expression of IL15 promotes effector differentiation and sustained proliferative capacity in ALPPL2-specific human CAR T cells\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/19\/htra1-macrophages-induce-t-cells-egress-through-crip1-nf-%ce%bab-cxcl12-to-limit-the-effects-of-immunotherapy-in-triple-negative-breast-cancer\/\">HTRA1+ macrophages induce T cells egress through CRIP1\/NF-\u03baB\/CXCL12 to limit the effects of immunotherapy in triple-negative breast cancer<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-19T20:43:13+01:00\" class=\"wp-block-latest-posts__post-date\">19 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Mar 19. doi: 10.1158\/2326-6066.CIR-25-1138. Online ahead of print. ABSTRACT The variation in immunotherapy responses among patients with triple-negative breast cancer (TNBC) is attributed to the high heterogeneity of tumor immune components, in which macrophages play a key role. Hence, identification of key macrophage subpopulations associated with immunotherapy efficacy could provide important &#8230; <a title=\"HTRA1+ macrophages induce T cells egress through CRIP1\/NF-\u03baB\/CXCL12 to limit the effects of immunotherapy in triple-negative breast cancer\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/19\/htra1-macrophages-induce-t-cells-egress-through-crip1-nf-%ce%bab-cxcl12-to-limit-the-effects-of-immunotherapy-in-triple-negative-breast-cancer\/\" aria-label=\"Read more about HTRA1+ macrophages induce T cells egress through CRIP1\/NF-\u03baB\/CXCL12 to limit the effects of immunotherapy in triple-negative breast cancer\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/19\/foxm1-specific-tcr-engineered-t-cells-target-non-small-cell-lung-cancer\/\">FOXM1-specific TCR-engineered T cells target non-small cell lung cancer<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-19T20:43:13+01:00\" class=\"wp-block-latest-posts__post-date\">19 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Mar 19. doi: 10.1158\/2326-6066.CIR-25-0605. Online ahead of print. ABSTRACT FOXM1 is highly expressed in various cancer types and considered a key driver of cancer progression. Accordingly, we evaluated the immunogenicity of FOXM1 and investigated the feasibility of targeting this transcription factor using T cell receptor (TCR) engineering. We identified epitopes derived &#8230; <a title=\"FOXM1-specific TCR-engineered T cells target non-small cell lung cancer\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/19\/foxm1-specific-tcr-engineered-t-cells-target-non-small-cell-lung-cancer\/\" aria-label=\"Read more about FOXM1-specific TCR-engineered T cells target non-small cell lung cancer\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/18\/capturing-and-tracking-clonal-t-cell-response-to-cancer-neoantigens\/\">Capturing and tracking clonal T cell response to cancer neoantigens<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-18T00:39:22+01:00\" class=\"wp-block-latest-posts__post-date\">18 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Mar 17. doi: 10.1158\/2326-6066.CIR-24-1216. Online ahead of print. ABSTRACT In humans and mice, the T cell receptor (TCR) of each effector\/memory T cell clone recognizes from one to several cognate peptide-MHC complexes (pMHC). Limited knowledge on TCR repertoire specificities restricts our capacity to rationally interpret this information, both diagnostically and in &#8230; <a title=\"Capturing and tracking clonal T cell response to cancer neoantigens\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/18\/capturing-and-tracking-clonal-t-cell-response-to-cancer-neoantigens\/\" aria-label=\"Read more about Capturing and tracking clonal T cell response to cancer neoantigens\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/14\/il-1r2-deficiency-unleashes-neutrophil-mediated-antitumor-potential-in-sarcoma\/\">IL-1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-14T00:43:54+01:00\" class=\"wp-block-latest-posts__post-date\">14 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Mar 13. doi: 10.1158\/2326-6066.CIR-25-0651. Online ahead of print. ABSTRACT Interleukin-1 (IL-1) plays dual functions in cancer. It promotes cancer-related inflammation and progression, but also influences leukocyte functional activation. IL-1 receptor 2 (IL-1R2) functions as an IL-1 decoy receptor, inhibiting IL-1 activity. Here, we investigated the contribution of IL-1R2 in tuning IL-1-dependent &#8230; <a title=\"IL-1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/14\/il-1r2-deficiency-unleashes-neutrophil-mediated-antitumor-potential-in-sarcoma\/\" aria-label=\"Read more about IL-1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/05\/response-of-b-cells-specific-for-polyomavirus-derived-oncoprotein-is-predictive-of-merkel-cell-carcinoma-tumor-control\/\">Response of B cells specific for polyomavirus-derived oncoprotein is predictive of Merkel cell carcinoma tumor control<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-05T01:20:03+01:00\" class=\"wp-block-latest-posts__post-date\">5 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Mar 4. doi: 10.1158\/2326-6066.CIR-25-0950. Online ahead of print. ABSTRACT Merkel cell carcinomas (MCC) typically arise from clonal integration of the Merkel cell polyomavirus. Immunogenic viral oncoproteins then lead to tumorigenesis. Oncoprotein-specific T cells are essential for anti-MCC immunity, but it is unclear whether B cells promote tumor control. Here, we analyzed &#8230; <a title=\"Response of B cells specific for polyomavirus-derived oncoprotein is predictive of Merkel cell carcinoma tumor control\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/05\/response-of-b-cells-specific-for-polyomavirus-derived-oncoprotein-is-predictive-of-merkel-cell-carcinoma-tumor-control\/\" aria-label=\"Read more about Response of B cells specific for polyomavirus-derived oncoprotein is predictive of Merkel cell carcinoma tumor control\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/04\/a-sampling-of-highlights-from-the-literature-article-recommendations-from-our-deputy-and-senior-editors-10\/\">A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-04T14:08:10+01:00\" class=\"wp-block-latest-posts__post-date\">4 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Mar 4;14(3):373. doi: 10.1158\/2326-6066.CIR-14-3-WWR. NO ABSTRACT PMID:41777151 | DOI:10.1158\/2326-6066.CIR-14-3-WWR<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/28\/constitutive-stat3-signaling-in-comparison-to-stat5-enhances-car-t-cell-efficacy-and-lowers-systemic-toxicity\/\">Constitutive STAT3 signaling, in comparison to STAT5, enhances CAR T cell efficacy and lowers systemic toxicity<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-28T01:39:55+01:00\" class=\"wp-block-latest-posts__post-date\">28 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Feb 27. doi: 10.1158\/2326-6066.CIR-25-0611. Online ahead of print. ABSTRACT Providing cytokine signaling is a key strategy to boost the efficacy of chimeric antigen receptor (CAR) T cell therapy. However, the individual roles of key downstream mediators, STAT3 and STAT5, remain incompletely understood. In this study, we engineered CAR T cells to &#8230; <a title=\"Constitutive STAT3 signaling, in comparison to STAT5, enhances CAR T cell efficacy and lowers systemic toxicity\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/28\/constitutive-stat3-signaling-in-comparison-to-stat5-enhances-car-t-cell-efficacy-and-lowers-systemic-toxicity\/\" aria-label=\"Read more about Constitutive STAT3 signaling, in comparison to STAT5, enhances CAR T cell efficacy and lowers systemic toxicity\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/28\/integrated-single-cell-profiling-reveals-dichotomous-nk-cell-populations-associated-with-immunosuppression-in-solid-tumors\/\">Integrated Single-Cell Profiling Reveals Dichotomous NK Cell Populations Associated with Immunosuppression in Solid Tumors<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-28T01:39:55+01:00\" class=\"wp-block-latest-posts__post-date\">28 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Feb 27. doi: 10.1158\/2326-6066.CIR-25-1229. Online ahead of print. ABSTRACT Natural killer (NK) cells represent key effectors of antitumor immunity, yet emerging evidence highlights populations with distinct roles in cancer. Despite such expanded diversity within the NK cell repertoire, we lack an understanding of how this heterogeneity impacts immune responses and downstream &#8230; <a title=\"Integrated Single-Cell Profiling Reveals Dichotomous NK Cell Populations Associated with Immunosuppression in Solid Tumors\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/28\/integrated-single-cell-profiling-reveals-dichotomous-nk-cell-populations-associated-with-immunosuppression-in-solid-tumors\/\" aria-label=\"Read more about Integrated Single-Cell Profiling Reveals Dichotomous NK Cell Populations Associated with Immunosuppression in Solid Tumors\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/26\/loss-of-mir-29a-b1-cluster-reprograms-the-tumor-microenvironment-and-contributes-to-immunosuppression-in-lung-cancer\/\">Loss of miR-29a\/b1 cluster reprograms the tumor microenvironment and contributes to immunosuppression in lung cancer<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-26T00:53:49+01:00\" class=\"wp-block-latest-posts__post-date\">26 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Feb 25. doi: 10.1158\/2326-6066.CIR-25-1060. Online ahead of print. ABSTRACT Immune checkpoint inhibitors (ICI), including those that block PD-1\/PD-L1, have revolutionized therapy for patients with non-small cell lung cancer. However, most patients demonstrate no clinical benefit or acquire resistance, even when tumors express PD-L1. This highlights the critical need to dissect tumor &#8230; <a title=\"Loss of miR-29a\/b1 cluster reprograms the tumor microenvironment and contributes to immunosuppression in lung cancer\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/26\/loss-of-mir-29a-b1-cluster-reprograms-the-tumor-microenvironment-and-contributes-to-immunosuppression-in-lung-cancer\/\" aria-label=\"Read more about Loss of miR-29a\/b1 cluster reprograms the tumor microenvironment and contributes to immunosuppression in lung cancer\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/26\/intra-tumoral-tertiary-lymphoid-structures-characterized-by-a-b-cell-related-signature-elicit-antitumor-effect-through-hapln3-in-hepatocellular-carcinoma\/\">Intra-tumoral tertiary lymphoid structures characterized by a B cell-related signature elicit antitumor effect through HAPLN3 in hepatocellular carcinoma<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-26T00:53:49+01:00\" class=\"wp-block-latest-posts__post-date\">26 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Feb 25. doi: 10.1158\/2326-6066.CIR-25-0758. Online ahead of print. ABSTRACT The existence of intra-tumoral tertiary lymphoid structures (TLSs) has been reported to be correlated with reduced recurrence of hepatocellular carcinoma (HCC). However, the cellular characteristics and driving mechanism of TLSs in HCC remain largely unknown. In this study, we compared clinical outcomes &#8230; <a title=\"Intra-tumoral tertiary lymphoid structures characterized by a B cell-related signature elicit antitumor effect through HAPLN3 in hepatocellular carcinoma\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/26\/intra-tumoral-tertiary-lymphoid-structures-characterized-by-a-b-cell-related-signature-elicit-antitumor-effect-through-hapln3-in-hepatocellular-carcinoma\/\" aria-label=\"Read more about Intra-tumoral tertiary lymphoid structures characterized by a B cell-related signature elicit antitumor effect through HAPLN3 in hepatocellular carcinoma\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/25\/vsig4-restricts-hepatocellular-carcinoma-control-by-suppressing-tumor-specific-cd8-t-cell-immunity-in-the-tumor-microenvironment\/\">VSIG4 restricts hepatocellular carcinoma control by suppressing tumor-specific CD8+ T cell immunity in the tumor microenvironment<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-25T19:46:57+01:00\" class=\"wp-block-latest-posts__post-date\">25 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Feb 25. doi: 10.1158\/2326-6066.CIR-25-0836. Online ahead of print. ABSTRACT Immunotherapies have revolutionized the treatment of hepatocellular carcinoma (HCC), yet their response rates remain limited, highlighting the need for new therapeutic targets. In this study, we found that VSIG4 (V-set and immunoglobulin domain containing 4) is predominantly expressed by macrophages in both &#8230; <a title=\"VSIG4 restricts hepatocellular carcinoma control by suppressing tumor-specific CD8+ T cell immunity in the tumor microenvironment\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/25\/vsig4-restricts-hepatocellular-carcinoma-control-by-suppressing-tumor-specific-cd8-t-cell-immunity-in-the-tumor-microenvironment\/\" aria-label=\"Read more about VSIG4 restricts hepatocellular carcinoma control by suppressing tumor-specific CD8+ T cell immunity in the tumor microenvironment\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/25\/engineered-ccr7-overexpression-enhances-nodal-car-t-cell-homing-and-cytotoxicity-toward-b-cell-lymphoma\/\">Engineered CCR7 overexpression enhances nodal CAR-T cell homing and cytotoxicity toward B cell lymphoma<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-25T01:28:06+01:00\" class=\"wp-block-latest-posts__post-date\">25 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Feb 24. doi: 10.1158\/2326-6066.CIR-25-1381. Online ahead of print. ABSTRACT Anti-CD19 chimeric antigen receptor (CAR) therapy demonstrated remarkable efficacy against hematological malignancies. However, B cell malignancies with lymph node (LN) involvement frequently remain resistant. Here, we show that CAR T cells downregulated the chemokine receptor CCR7, crucial for nodal homing, during manufacturing. &#8230; <a title=\"Engineered CCR7 overexpression enhances nodal CAR-T cell homing and cytotoxicity toward B cell lymphoma\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/25\/engineered-ccr7-overexpression-enhances-nodal-car-t-cell-homing-and-cytotoxicity-toward-b-cell-lymphoma\/\" aria-label=\"Read more about Engineered CCR7 overexpression enhances nodal CAR-T cell homing and cytotoxicity toward B cell lymphoma\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/21\/baseline-tumor-features-and-systemic-immune-dynamics-underlying-efficacy-in-mss-metastatic-colorectal-cancer-treated-with-regorafenib-ipilimumab-and-nivolumab\/\">Baseline tumor features and systemic immune dynamics underlying efficacy in MSS metastatic colorectal cancer treated with regorafenib, ipilimumab, and nivolumab<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-21T04:11:54+01:00\" class=\"wp-block-latest-posts__post-date\">21 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Feb 20. doi: 10.1158\/2326-6066.CIR-25-0243. Online ahead of print. ABSTRACT Microsatellite-stable metastatic colorectal cancer (MSS mCRC) remains resistant to conventional immunotherapies. In a phase I trial, we observed encouraging efficacy of the combination of regorafenib, ipilimumab, and nivolumab (RIN), with a 27.6% overall response rate and a median overall survival of 20 &#8230; <a title=\"Baseline tumor features and systemic immune dynamics underlying efficacy in MSS metastatic colorectal cancer treated with regorafenib, ipilimumab, and nivolumab\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/21\/baseline-tumor-features-and-systemic-immune-dynamics-underlying-efficacy-in-mss-metastatic-colorectal-cancer-treated-with-regorafenib-ipilimumab-and-nivolumab\/\" aria-label=\"Read more about Baseline tumor features and systemic immune dynamics underlying efficacy in MSS metastatic colorectal cancer treated with regorafenib, ipilimumab, and nivolumab\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/21\/potent-cytotoxic-tumor-infiltrating-lymphocytes-can-be-generated-from-immune-excluded-chondrosarcomas-using-regulatable-membrane-bound-il15\/\">Potent cytotoxic tumor-infiltrating lymphocytes can be generated from immune-excluded chondrosarcomas using regulatable membrane-bound IL15<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-21T04:11:54+01:00\" class=\"wp-block-latest-posts__post-date\">21 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Feb 20. doi: 10.1158\/2326-6066.CIR-25-1016. Online ahead of print. ABSTRACT Autologous tumor-infiltrating lymphocyte (TIL) cell therapy is showing promising efficacy against immunologically &#8220;hot&#8221; tumors such as melanoma, cervical cancer, and renal cancer. However, generation of tumoricidal TIL from cold tumors with a low tumor mutational burden, such as many sarcoma types, poses &#8230; <a title=\"Potent cytotoxic tumor-infiltrating lymphocytes can be generated from immune-excluded chondrosarcomas using regulatable membrane-bound IL15\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/21\/potent-cytotoxic-tumor-infiltrating-lymphocytes-can-be-generated-from-immune-excluded-chondrosarcomas-using-regulatable-membrane-bound-il15\/\" aria-label=\"Read more about Potent cytotoxic tumor-infiltrating lymphocytes can be generated from immune-excluded chondrosarcomas using regulatable membrane-bound IL15\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/13\/clk1-promotes-myeloid-derived-suppressor-cell-trafficking-and-reprograms-the-tumor-microenvironment-by-activating-hippo-yap-signaling-in-colorectal-cancer\/\">CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by activating Hippo\/YAP signaling in Colorectal Cancer<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-13T19:08:08+01:00\" class=\"wp-block-latest-posts__post-date\">13 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Feb 13. doi: 10.1158\/2326-6066.CIR-25-0766. Online ahead of print. ABSTRACT Colorectal cancer (CRC) is a highly heterogeneous malignancy characterized by complex interactions between tumor cells and the immune system. The tumor microenvironment (TME) plays a crucial role in CRC progression and response to therapy. However, the mechanisms regulating TME composition remain poorly &#8230; <a title=\"CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by activating Hippo\/YAP signaling in Colorectal Cancer\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/13\/clk1-promotes-myeloid-derived-suppressor-cell-trafficking-and-reprograms-the-tumor-microenvironment-by-activating-hippo-yap-signaling-in-colorectal-cancer\/\" aria-label=\"Read more about CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by activating Hippo\/YAP signaling in Colorectal Cancer\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/13\/ex-vivo-expansion-of-melanoma-tumor-infiltrating-lymphocytes-leads-to-a-dominant-exhausted-t-cell-population-with-lack-of-memory-markers\/\">Ex vivo expansion of melanoma tumor infiltrating lymphocytes leads to a dominant exhausted T cell population with lack of memory markers<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-13T19:08:08+01:00\" class=\"wp-block-latest-posts__post-date\">13 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Feb 13. doi: 10.1158\/2326-6066.CIR-25-0798. Online ahead of print. ABSTRACT Tumor infiltrating lymphocytes (TILs) can be isolated from patient tumors, greatly expanded ex vivo, and returned to the patient for therapeutic effect. Recent clinical trials have highlighted the efficacy of TILs for a subset of patients and supported FDA approval for melanoma. &#8230; <a title=\"Ex vivo expansion of melanoma tumor infiltrating lymphocytes leads to a dominant exhausted T cell population with lack of memory markers\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/13\/ex-vivo-expansion-of-melanoma-tumor-infiltrating-lymphocytes-leads-to-a-dominant-exhausted-t-cell-population-with-lack-of-memory-markers\/\" aria-label=\"Read more about Ex vivo expansion of melanoma tumor infiltrating lymphocytes leads to a dominant exhausted T cell population with lack of memory markers\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/13\/targeted-lipid-nanoparticle-delivery-of-fap-car-mrna-enables-potent-in-vivo-t-cell-engineering-against-pancreatic-tumors\/\">Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-Cell Engineering Against Pancreatic Tumors<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-13T19:08:08+01:00\" class=\"wp-block-latest-posts__post-date\">13 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Feb 13. doi: 10.1158\/2326-6066.CIR-25-0663. Online ahead of print. ABSTRACT Fibroblast activation protein (FAP), which is highly expressed on cancer-associated fibroblasts (CAFs), is a promising therapeutic target to achieve normalization of the tumor microenvironment. We previously established an ex vivo retroviral-transduced FAP-specific chimeric antigen receptor (FAP-CAR) T-cell approach to deplete FAP+ CAFs &#8230; <a title=\"Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-Cell Engineering Against Pancreatic Tumors\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/13\/targeted-lipid-nanoparticle-delivery-of-fap-car-mrna-enables-potent-in-vivo-t-cell-engineering-against-pancreatic-tumors\/\" aria-label=\"Read more about Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-Cell Engineering Against Pancreatic Tumors\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/13\/the-presence-of-cd11c-b-cells-with-potent-effector-memory-phenotype-in-lung-adenocarcinoma-correlates-with-overall-patient-survival\/\">The presence of CD11c+ B cells with potent effector memory phenotype in lung adenocarcinoma correlates with overall patient survival<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-13T19:08:08+01:00\" class=\"wp-block-latest-posts__post-date\">13 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Feb 13. doi: 10.1158\/2326-6066.CIR-25-0635. Online ahead of print. ABSTRACT Tumor-infiltrating B lymphocytes (TIL-Bs) are increasingly recognized as favorable prognostic markers in multiple cancer types and the mechanisms underlying this are being actively investigated. In this study of TIL-Bs, we identified CD79A as a reliable quantifier of B lymphocytes and evaluated transcriptomic &#8230; <a title=\"The presence of CD11c+ B cells with potent effector memory phenotype in lung adenocarcinoma correlates with overall patient survival\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/13\/the-presence-of-cd11c-b-cells-with-potent-effector-memory-phenotype-in-lung-adenocarcinoma-correlates-with-overall-patient-survival\/\" aria-label=\"Read more about The presence of CD11c+ B cells with potent effector memory phenotype in lung adenocarcinoma correlates with overall patient survival\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/13\/wtx-124-a-conditionally-activated-wild-type-il2-maximizes-the-therapeutic-index-of-il2-unlike-non-alpha-muteins\/\">WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike &#8220;Non-Alpha&#8221; Muteins<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-13T19:08:08+01:00\" class=\"wp-block-latest-posts__post-date\">13 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Feb 13:OF1-OF16. doi: 10.1158\/2326-6066.CIR-25-0558. Online ahead of print. ABSTRACT High-dose interleukin 2 (HD IL2) produces durable responses in patients with advanced cancer, but its use is limited by life-threatening toxicities such as vascular leak syndrome (VLS). To improve the therapeutic index for IL2, a class of IL2 molecules has been engineered &#8230; <a title=\"WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike &#8220;Non-Alpha&#8221; Muteins\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/13\/wtx-124-a-conditionally-activated-wild-type-il2-maximizes-the-therapeutic-index-of-il2-unlike-non-alpha-muteins\/\" aria-label=\"Read more about WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike &#8220;Non-Alpha&#8221; Muteins\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/11\/up-regulation-of-an-epithelial-mirna-is-associated-with-immune-evasion-in-progressive-bronchial-premalignant-lesions\/\">Up-regulation of an epithelial miRNA is associated with immune evasion in progressive bronchial premalignant lesions<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-11T19:11:10+01:00\" class=\"wp-block-latest-posts__post-date\">11 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Feb 11. doi: 10.1158\/2326-6066.CIR-25-0431. Online ahead of print. ABSTRACT Bronchial premalignant lesions (PMLs), precursors of lung squamous cell carcinoma, have distinct molecular subtypes. The proliferative subtype, enriched with bronchial dysplasia, had decreased expression of an antigen processing\/presentation gene co-expression module in progressive\/persistent versus regressive PMLs, suggesting a functional impact of these &#8230; <a title=\"Up-regulation of an epithelial miRNA is associated with immune evasion in progressive bronchial premalignant lesions\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/11\/up-regulation-of-an-epithelial-mirna-is-associated-with-immune-evasion-in-progressive-bronchial-premalignant-lesions\/\" aria-label=\"Read more about Up-regulation of an epithelial miRNA is associated with immune evasion in progressive bronchial premalignant lesions\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/11\/genomic-and-immune-landscape-of-recurrent-and-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-progressing-on-anti-pd1-treatment\/\">Genomic and immune landscape of recurrent and\/or metastatic squamous cell carcinoma of the head and neck progressing on anti-PD1 treatment<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-11T01:41:02+01:00\" class=\"wp-block-latest-posts__post-date\">11 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Feb 10. doi: 10.1158\/2326-6066.CIR-25-0979. Online ahead of print. ABSTRACT Anti-PD1 therapies improve survival in recurrent\/metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN), but only a minority of patients achieve durable responses. The mechanisms driving resistance to anti-PD1 in SCCHN remain poorly understood. Using the IMMUcan multi-omics workflow, we &#8230; <a title=\"Genomic and immune landscape of recurrent and\/or metastatic squamous cell carcinoma of the head and neck progressing on anti-PD1 treatment\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/11\/genomic-and-immune-landscape-of-recurrent-and-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-progressing-on-anti-pd1-treatment\/\" aria-label=\"Read more about Genomic and immune landscape of recurrent and\/or metastatic squamous cell carcinoma of the head and neck progressing on anti-PD1 treatment\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/07\/neoadjuvant-endocrine-treatment-plus-mammaglobin-a-dna-vaccine-induces-antitumor-immune-responses-in-the-primary-tumor-and-peripheral-blood-of-breast-cancer-patients-insights-from-a-phase-1b-clinical\/\">Neoadjuvant endocrine treatment plus mammaglobin-A DNA vaccine induces antitumor immune responses in the primary tumor and peripheral blood of breast cancer patients: Insights from a phase 1b clinical trial<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-07T00:33:14+01:00\" class=\"wp-block-latest-posts__post-date\">7 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Feb 6. doi: 10.1158\/2326-6066.CIR-25-0666. Online ahead of print. ABSTRACT Tumor-associated antigen (TAA) vaccines are being explored as a strategy to induce antitumor immune responses. Mammaglobin-A (Mam-A) is a TAA expressed in &gt;50% of breast cancer (BC) patients. Previously, we have shown that Mam-A DNA vaccines induce antitumor immune responses in patients &#8230; <a title=\"Neoadjuvant endocrine treatment plus mammaglobin-A DNA vaccine induces antitumor immune responses in the primary tumor and peripheral blood of breast cancer patients: Insights from a phase 1b clinical trial\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/07\/neoadjuvant-endocrine-treatment-plus-mammaglobin-a-dna-vaccine-induces-antitumor-immune-responses-in-the-primary-tumor-and-peripheral-blood-of-breast-cancer-patients-insights-from-a-phase-1b-clinical\/\" aria-label=\"Read more about Neoadjuvant endocrine treatment plus mammaglobin-A DNA vaccine induces antitumor immune responses in the primary tumor and peripheral blood of breast cancer patients: Insights from a phase 1b clinical trial\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/04\/concurrent-pituitary-and-thyroid-immune-related-adverse-events-after-immune-checkpoint-inhibitors-associated-with-hla-dr15-related-haplotypes\/\">Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15-related Haplotypes<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-04T21:22:49+01:00\" class=\"wp-block-latest-posts__post-date\">4 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Feb 4. doi: 10.1158\/2326-6066.CIR-25-0693. Online ahead of print. ABSTRACT Some patients undergoing immune checkpoint blockade treatment develop immune-related adverse events (irAEs) affecting multiple organs, but whether pituitary and thyroid dysfunction are prone to co-occur is unclear. A total of 1,014 patients treated at Nagoya University Hospital were prospectively assessed for pituitary &#8230; <a title=\"Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15-related Haplotypes\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/04\/concurrent-pituitary-and-thyroid-immune-related-adverse-events-after-immune-checkpoint-inhibitors-associated-with-hla-dr15-related-haplotypes\/\" aria-label=\"Read more about Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15-related Haplotypes\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/03\/a-sampling-of-highlights-from-the-literature-article-recommendations-from-our-deputy-and-senior-editors-9\/\">A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-03T13:40:46+01:00\" class=\"wp-block-latest-posts__post-date\">3 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Feb 3;14(2):181. doi: 10.1158\/2326-6066.CIR-14-2-WWR. NO ABSTRACT PMID:41630580 | DOI:10.1158\/2326-6066.CIR-14-2-WWR<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/31\/ccl1-amfr-facilitates-glioblastoma-progression-by-modulating-the-crosstalk-between-glioma-cells-and-tumor-associated-macrophages\/\">CCL1-AMFR facilitates glioblastoma progression by modulating the crosstalk between glioma cells and tumor-associated macrophages<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-31T03:12:45+01:00\" class=\"wp-block-latest-posts__post-date\">31 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 30. doi: 10.1158\/2326-6066.CIR-25-0646. Online ahead of print. ABSTRACT The immunosuppressive tumor microenvironment (TME) in glioblastoma (GBM) is predominantly shaped by tumor-associated macrophages (TAMs), yet the key chemokine axes driving immunosuppression and progression remain poorly defined. In this study, we identified the CCL1-AMFR axis as a critical contributor to GBM progression &#8230; <a title=\"CCL1-AMFR facilitates glioblastoma progression by modulating the crosstalk between glioma cells and tumor-associated macrophages\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/31\/ccl1-amfr-facilitates-glioblastoma-progression-by-modulating-the-crosstalk-between-glioma-cells-and-tumor-associated-macrophages\/\" aria-label=\"Read more about CCL1-AMFR facilitates glioblastoma progression by modulating the crosstalk between glioma cells and tumor-associated macrophages\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/28\/computational-modeling-of-cellular-influence-delineates-functionally-relevant-and-distinct-cellular-neighborhoods-in-primary-and-metastatic-pancreatic-ductal-adenocarcinoma\/\">Computational modeling of cellular influence delineates functionally relevant and distinct cellular neighborhoods in primary and metastatic pancreatic ductal adenocarcinoma<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-28T07:46:47+01:00\" class=\"wp-block-latest-posts__post-date\">28 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 23. doi: 10.1158\/2326-6066.CIR-25-0844. Online ahead of print. ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, with liver metastases significantly worsening outcomes. However, features of the tumor microenvironment (TME) that are distinct between primary and metastatic sites remain poorly defined. Cellular neighborhoods within the TME are recognized as functional &#8230; <a title=\"Computational modeling of cellular influence delineates functionally relevant and distinct cellular neighborhoods in primary and metastatic pancreatic ductal adenocarcinoma\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/28\/computational-modeling-of-cellular-influence-delineates-functionally-relevant-and-distinct-cellular-neighborhoods-in-primary-and-metastatic-pancreatic-ductal-adenocarcinoma\/\" aria-label=\"Read more about Computational modeling of cellular influence delineates functionally relevant and distinct cellular neighborhoods in primary and metastatic pancreatic ductal adenocarcinoma\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/27\/removal-of-interstitial-hyaluronan-facilitates-subcutaneous-administration-and-lymphatic-delivery-of-anti-ctla4-and-improves-antitumor-efficacy\/\">Removal of Interstitial Hyaluronan Facilitates Subcutaneous Administration and Lymphatic Delivery of Anti-CTLA4 and Improves Antitumor Efficacy<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-27T19:34:55+01:00\" class=\"wp-block-latest-posts__post-date\">27 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 27:OF1-OF13. doi: 10.1158\/2326-6066.CIR-25-0256. Online ahead of print. ABSTRACT Subcutaneous administration is an increasingly patient-preferred, alternative route of administration for monoclonal antibodies (mAb). To overcome the dose-volume restriction with subcutaneous administration and enable the large mAb doses typically required for immunotherapy, recombinant human hyaluronidase PH20 is co-dosed to transiently depolymerize hyaluronan &#8230; <a title=\"Removal of Interstitial Hyaluronan Facilitates Subcutaneous Administration and Lymphatic Delivery of Anti-CTLA4 and Improves Antitumor Efficacy\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/27\/removal-of-interstitial-hyaluronan-facilitates-subcutaneous-administration-and-lymphatic-delivery-of-anti-ctla4-and-improves-antitumor-efficacy\/\" aria-label=\"Read more about Removal of Interstitial Hyaluronan Facilitates Subcutaneous Administration and Lymphatic Delivery of Anti-CTLA4 and Improves Antitumor Efficacy\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/22\/regulatory-t-cell-sensing-of-extracellular-atp-via-p2rx7-promotes-their-accumulation-and-suppression-and-drives-lung-tumor-growth\/\">Regulatory T-cell sensing of extracellular ATP via P2RX7 promotes their accumulation and suppression and drives lung tumor growth<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-22T00:50:52+01:00\" class=\"wp-block-latest-posts__post-date\">22 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 21. doi: 10.1158\/2326-6066.CIR-25-0567. Online ahead of print. ABSTRACT Lung cancer is the leading cause of cancer-related deaths worldwide and, despite advances in treatment, immune suppression remains an obstacle to effective therapy. Effector CD4+ T cells (CD4+ Teffs) are critical for antitumor immunity, but their function is often inhibited by regulatory &#8230; <a title=\"Regulatory T-cell sensing of extracellular ATP via P2RX7 promotes their accumulation and suppression and drives lung tumor growth\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/22\/regulatory-t-cell-sensing-of-extracellular-atp-via-p2rx7-promotes-their-accumulation-and-suppression-and-drives-lung-tumor-growth\/\" aria-label=\"Read more about Regulatory T-cell sensing of extracellular ATP via P2RX7 promotes their accumulation and suppression and drives lung tumor growth\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/22\/ex-vivo-immuno-oncology-platform-reveals-spatial-t-cell-infiltration-patterns-linked-to-atr-inhibition-responses-in-high-grade-serous-ovarian-cancer\/\">Ex Vivo Immuno-Oncology Platform Reveals Spatial T Cell Infiltration Patterns Linked to ATR Inhibition Responses in High-Grade Serous Ovarian Cancer<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-22T00:50:52+01:00\" class=\"wp-block-latest-posts__post-date\">22 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 21. doi: 10.1158\/2326-6066.CIR-25-0743. Online ahead of print. ABSTRACT Identifying new therapeutic approaches in high-grade serous ovarian cancer (HGSC) requires the development of more accurate preclinical models that replicate the patient-specific tumor and its microenvironment. To address this, we established immunocompetent patient-derived cultures (iPDCs) for HGSC, cultured on a physiologically relevant &#8230; <a title=\"Ex Vivo Immuno-Oncology Platform Reveals Spatial T Cell Infiltration Patterns Linked to ATR Inhibition Responses in High-Grade Serous Ovarian Cancer\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/22\/ex-vivo-immuno-oncology-platform-reveals-spatial-t-cell-infiltration-patterns-linked-to-atr-inhibition-responses-in-high-grade-serous-ovarian-cancer\/\" aria-label=\"Read more about Ex Vivo Immuno-Oncology Platform Reveals Spatial T Cell Infiltration Patterns Linked to ATR Inhibition Responses in High-Grade Serous Ovarian Cancer\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/21\/anti-b-cell-maturation-antigen-chimeric-antigen-receptor-t-cell-therapy-bb21217-for-relapsed-and-refractory-multiple-myeloma-results-from-the-phase-1-crb-402-study\/\">Anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy bb21217 for relapsed and refractory multiple myeloma: results from the phase 1 CRB-402 study<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-21T19:48:25+01:00\" class=\"wp-block-latest-posts__post-date\">21 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 21. doi: 10.1158\/2326-6066.CIR-24-0527. Online ahead of print. ABSTRACT Chimeric antigen receptor (CAR) T-cell therapy enriched for a memory-like phenotype may persist and function longer than a non-enriched product, thereby improving duration of response (DOR). We conducted a phase 1 study with bb21217 (NCT03274219), an anti-B-cell maturation antigen CAR T-cell therapy &#8230; <a title=\"Anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy bb21217 for relapsed and refractory multiple myeloma: results from the phase 1 CRB-402 study\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/21\/anti-b-cell-maturation-antigen-chimeric-antigen-receptor-t-cell-therapy-bb21217-for-relapsed-and-refractory-multiple-myeloma-results-from-the-phase-1-crb-402-study\/\" aria-label=\"Read more about Anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy bb21217 for relapsed and refractory multiple myeloma: results from the phase 1 CRB-402 study\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/21\/medium-chain-fatty-acid-receptor-gpr84-modulates-cytotoxic-cd8-t-cells-antitumor-immunity-through-metabolic-reprogramming\/\">Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T cells Antitumor Immunity Through Metabolic Reprogramming<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-21T01:35:09+01:00\" class=\"wp-block-latest-posts__post-date\">21 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 20. doi: 10.1158\/2326-6066.CIR-25-0695. Online ahead of print. ABSTRACT GPR84 is a medium-chain free fatty acid receptor predominantly expressed in myeloid cells. Previous studies have identified GPR84 as an enhancer of the pro-inflammatory myeloid cell responses and a regulator of metabolic homeostasis. However, the role of GPR84 in T cell function &#8230; <a title=\"Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T cells Antitumor Immunity Through Metabolic Reprogramming\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/21\/medium-chain-fatty-acid-receptor-gpr84-modulates-cytotoxic-cd8-t-cells-antitumor-immunity-through-metabolic-reprogramming\/\" aria-label=\"Read more about Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T cells Antitumor Immunity Through Metabolic Reprogramming\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/16\/conditional-il4i1-inactivation-triggers-tumor-associated-macrophage-reprogramming-and-cd8-t-cell-reactivation-to-control-melanoma-progression\/\">Conditional IL4I1 inactivation triggers tumor-associated macrophage reprogramming and CD8+ T-cell reactivation to control melanoma progression<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-16T23:47:49+01:00\" class=\"wp-block-latest-posts__post-date\">16 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 15. doi: 10.1158\/2326-6066.CIR-24-1159. Online ahead of print. ABSTRACT Tumor-associated macrophages (TAMs) represent the main immune population infiltrating cancers, and their abundance is generally correlated with a poor prognosis. The acquisition of protumor properties by TAMs involves several mechanisms, including expression of immunosuppressive enzymes. In this study, we explored the role &#8230; <a title=\"Conditional IL4I1 inactivation triggers tumor-associated macrophage reprogramming and CD8+ T-cell reactivation to control melanoma progression\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/16\/conditional-il4i1-inactivation-triggers-tumor-associated-macrophage-reprogramming-and-cd8-t-cell-reactivation-to-control-melanoma-progression\/\" aria-label=\"Read more about Conditional IL4I1 inactivation triggers tumor-associated macrophage reprogramming and CD8+ T-cell reactivation to control melanoma progression\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/14\/targeting-tumor-draining-lymph-nodes-to-improve-the-therapeutic-potential-of-oncolytic-viruses\/\">Targeting Tumor-Draining Lymph Nodes to Improve the Therapeutic Potential of Oncolytic Viruses<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-14T19:05:59+01:00\" class=\"wp-block-latest-posts__post-date\">14 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 14:OF1-OF2. doi: 10.1158\/2326-6066.CIR-25-1596. Online ahead of print. ABSTRACT Oncolytic viruses (OV) are thought to mediate antitumor activity by killing tumor cells and inducing antitumor immunity, but how this happens is not well understood. In this issue, Ludwig and colleagues show that PVSRIPO, an oncolytic poliovirus being developed for glioblastoma, may &#8230; <a title=\"Targeting Tumor-Draining Lymph Nodes to Improve the Therapeutic Potential of Oncolytic Viruses\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/14\/targeting-tumor-draining-lymph-nodes-to-improve-the-therapeutic-potential-of-oncolytic-viruses\/\" aria-label=\"Read more about Targeting Tumor-Draining Lymph Nodes to Improve the Therapeutic Potential of Oncolytic Viruses\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/13\/taking-multiple-shots-on-goal-with-an-armed-invariant-nk-cell-approach\/\">Taking &#8220;Multiple Shots on Goal&#8221; with an Armed Invariant NK Cell Approach<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-13T19:46:41+01:00\" class=\"wp-block-latest-posts__post-date\">13 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 13:OF1-OF2. doi: 10.1158\/2326-6066.CIR-25-1344. Online ahead of print. ABSTRACT Adoptive T-cell therapies have shown limited efficacy against solid tumors, so new approaches are required. In this issue, Chantzoura and colleagues describe MiNK-215, a novel allogeneic fibroblast activation protein-targeting chimeric antigen receptor invariant NK T-cell therapy engineered to secrete IL15. They show &#8230; <a title=\"Taking &#8220;Multiple Shots on Goal&#8221; with an Armed Invariant NK Cell Approach\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/13\/taking-multiple-shots-on-goal-with-an-armed-invariant-nk-cell-approach\/\" aria-label=\"Read more about Taking &#8220;Multiple Shots on Goal&#8221; with an Armed Invariant NK Cell Approach\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/12\/cytometric-atlas-of-combination-immunotherapy-in-pancreatic-cancer-blood-based-signatures-reveal-vaccine-and-checkpoint-inhibitor-responses\/\">Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-12T19:27:26+01:00\" class=\"wp-block-latest-posts__post-date\">12 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 12. doi: 10.1158\/2326-6066.CIR-25-1126. Online ahead of print. ABSTRACT Combination vaccine and checkpoint inhibitor therapy has previously demonstrated immunologic responses in patients with pancreatic ductal adenocarcinoma (PDAC), although with limited efficacy. An urgent need to augment responses has warranted a deeper understanding of how each treatment modality contributes to the overall &#8230; <a title=\"Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/12\/cytometric-atlas-of-combination-immunotherapy-in-pancreatic-cancer-blood-based-signatures-reveal-vaccine-and-checkpoint-inhibitor-responses\/\" aria-label=\"Read more about Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/12\/a-randomized-phase-ii-study-crs207-gvax-plus-anti-pd1-and-anti-ctla4-recruits-mesothelin-and-mkras-specific-t-cells-into-pdac\/\">A randomized phase II study: CRS207\/GVAX plus anti-PD1 and anti-CTLA4 recruits mesothelin- and mKRAS-specific T cells into PDAC<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-12T19:27:26+01:00\" class=\"wp-block-latest-posts__post-date\">12 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 12. doi: 10.1158\/2326-6066.CIR-25-0545. Online ahead of print. ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal and has poor immunogenicity, warranting the use of vaccines to guide and recruit the immune response. Building on prior efforts to achieve clinical immunotherapeutic responses against PDAC, we conducted a phase II study (NCT03190265) that &#8230; <a title=\"A randomized phase II study: CRS207\/GVAX plus anti-PD1 and anti-CTLA4 recruits mesothelin- and mKRAS-specific T cells into PDAC\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/12\/a-randomized-phase-ii-study-crs207-gvax-plus-anti-pd1-and-anti-ctla4-recruits-mesothelin-and-mkras-specific-t-cells-into-pdac\/\" aria-label=\"Read more about A randomized phase II study: CRS207\/GVAX plus anti-PD1 and anti-CTLA4 recruits mesothelin- and mKRAS-specific T cells into PDAC\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/12\/training-tomorrows-leaders-in-cancer-immunology\/\">Training Tomorrow&#8217;s Leaders in Cancer Immunology<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-12T19:27:26+01:00\" class=\"wp-block-latest-posts__post-date\">12 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 12:OF1-OF8. doi: 10.1158\/2326-6066.CIR-25-1479. Online ahead of print. ABSTRACT The transition from trainee to independent investigator is one of the most challenging and formative phases of a scientific career. It requires not only scientific expertise but also the skills to lead, mentor, manage, and communicate effectively. The Arthur and Sandra Irving &#8230; <a title=\"Training Tomorrow&#8217;s Leaders in Cancer Immunology\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/12\/training-tomorrows-leaders-in-cancer-immunology\/\" aria-label=\"Read more about Training Tomorrow&#8217;s Leaders in Cancer Immunology\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/10\/pseudomonas-aeruginosa-exacerbates-bladder-cancer-progression-by-activating-cancer-driven-immunosuppression\/\">Pseudomonas aeruginosa exacerbates bladder cancer progression by activating cancer-driven immunosuppression<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-10T00:33:24+01:00\" class=\"wp-block-latest-posts__post-date\">10 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 9. doi: 10.1158\/2326-6066.CIR-25-0873. Online ahead of print. ABSTRACT Pseudomonas aeruginosa infection is still a serious problem among immunocompromised patients who have advanced urinary tract malignancies, yet the impact of P. aeruginosa on disease progression remains poorly defined. Here, we show that urinary tract infections (UTI) caused by P. aeruginosa exacerbated &#8230; <a title=\"Pseudomonas aeruginosa exacerbates bladder cancer progression by activating cancer-driven immunosuppression\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/10\/pseudomonas-aeruginosa-exacerbates-bladder-cancer-progression-by-activating-cancer-driven-immunosuppression\/\" aria-label=\"Read more about Pseudomonas aeruginosa exacerbates bladder cancer progression by activating cancer-driven immunosuppression\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/09\/microbial-derived-metabolites-and-their-impact-on-cancer-immunotherapy\/\">Microbial-Derived Metabolites and Their Impact on Cancer Immunotherapy<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-09T19:30:26+01:00\" class=\"wp-block-latest-posts__post-date\">9 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 9:OF1-OF11. doi: 10.1158\/2326-6066.CIR-25-1018. Online ahead of print. ABSTRACT The gut microbiome has emerged as a modulator of both cancer progression and patient responses to therapies like immune checkpoint inhibitors (ICI). Recent evidence highlights microbially derived metabolites as key regulators of immune response and tumor microenvironment dynamics. This review explores the &#8230; <a title=\"Microbial-Derived Metabolites and Their Impact on Cancer Immunotherapy\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/09\/microbial-derived-metabolites-and-their-impact-on-cancer-immunotherapy\/\" aria-label=\"Read more about Microbial-Derived Metabolites and Their Impact on Cancer Immunotherapy\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/09\/phase-ii-trial-of-interleukin-12-followed-by-interferon-alfa-2b-in-patients-with-metastatic-malignant-melanoma-results-from-calgb-500001-alliance\/\">Phase II trial of interleukin-12 followed by interferon alfa-2b in patients with metastatic malignant melanoma: Results from CALGB 500001 (Alliance)<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-09T02:19:38+01:00\" class=\"wp-block-latest-posts__post-date\">9 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 8. doi: 10.1158\/2326-6066.CIR-25-0880. Online ahead of print. ABSTRACT The ability of interleukin-12 (IL-12) to stimulate production of interferon gamma (IFN-\u03b3) suggested it might improve the efficacy of low dose interferon alpha (IFN-\u03b1). In this phase II trial, patients with metastatic malignant melanoma were administered recombinant human (rh) IL-12 followed by &#8230; <a title=\"Phase II trial of interleukin-12 followed by interferon alfa-2b in patients with metastatic malignant melanoma: Results from CALGB 500001 (Alliance)\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/09\/phase-ii-trial-of-interleukin-12-followed-by-interferon-alfa-2b-in-patients-with-metastatic-malignant-melanoma-results-from-calgb-500001-alliance\/\" aria-label=\"Read more about Phase II trial of interleukin-12 followed by interferon alfa-2b in patients with metastatic malignant melanoma: Results from CALGB 500001 (Alliance)\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/08\/a-sampling-of-highlights-from-the-literature-article-recommendations-from-our-deputy-and-senior-editors-8\/\">A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-08T13:09:52+01:00\" class=\"wp-block-latest-posts__post-date\">8 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 8;14(1):7. doi: 10.1158\/2326-6066.CIR-14-1-WWR. NO ABSTRACT PMID:41502309 | DOI:10.1158\/2326-6066.CIR-14-1-WWR<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/08\/the-next-chapter-of-cancer-immunology-research\/\">The Next Chapter of Cancer Immunology Research<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-08T13:09:51+01:00\" class=\"wp-block-latest-posts__post-date\">8 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 8;14(1):8-9. doi: 10.1158\/2326-6066.CIR-25-1391. NO ABSTRACT PMID:41502310 | DOI:10.1158\/2326-6066.CIR-25-1391<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/08\/il-10r-inhibition-induces-neutrophil-tumoricidal-activity\/\">IL-10R inhibition induces neutrophil tumoricidal activity<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-08T02:02:44+01:00\" class=\"wp-block-latest-posts__post-date\">8 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2026 Jan 7. doi: 10.1158\/2326-6066.CIR-25-0834. Online ahead of print. ABSTRACT While the role of neutrophils in modulating antitumor T cell responses has been extensively studied, their direct effects on tumor cells remains less well understood. In this study, we investigated whether neutrophils have the capacity to directly kill tumor cells independently of &#8230; <a title=\"IL-10R inhibition induces neutrophil tumoricidal activity\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/08\/il-10r-inhibition-induces-neutrophil-tumoricidal-activity\/\" aria-label=\"Read more about IL-10R inhibition induces neutrophil tumoricidal activity\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/30\/the-ccl17-ccr4-axis-is-critical-for-mutant-stat6-mediated-microenvironmental-remodelling-and-therapeutic-resistance-in-relapsed-refractory-diffuse-large-b-cell-lymphoma\/\">The CCL17-CCR4 axis is critical for mutant STAT6-mediated microenvironmental remodelling and therapeutic resistance in Relapsed\/Refractory Diffuse Large B-cell Lymphoma<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-12-30T02:14:25+01:00\" class=\"wp-block-latest-posts__post-date\">30 de December de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2025 Dec 29. doi: 10.1158\/2326-6066.CIR-25-0583. Online ahead of print. ABSTRACT Relapsed and refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) presents a significant challenge in hematology-oncology, with approximately 30-40% of DLBCL patients experiencing relapse or resistance to treatment. This underscores the urgent need to better understand the molecular mechanisms governing therapeutic resistance. Signal Transducer &#8230; <a title=\"The CCL17-CCR4 axis is critical for mutant STAT6-mediated microenvironmental remodelling and therapeutic resistance in Relapsed\/Refractory Diffuse Large B-cell Lymphoma\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/30\/the-ccl17-ccr4-axis-is-critical-for-mutant-stat6-mediated-microenvironmental-remodelling-and-therapeutic-resistance-in-relapsed-refractory-diffuse-large-b-cell-lymphoma\/\" aria-label=\"Read more about The CCL17-CCR4 axis is critical for mutant STAT6-mediated microenvironmental remodelling and therapeutic resistance in Relapsed\/Refractory Diffuse Large B-cell Lymphoma\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/09\/immunotherapy-inhibits-tumor-cholesterol-synthesis-via-the-ifn-%ce%b3-%ce%b9rf1-srebf2-axis\/\">Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFN-\u03b3-\u0399RF1-SREBF2 Axis<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-12-09T19:57:46+01:00\" class=\"wp-block-latest-posts__post-date\">9 de December de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2025 Dec 9. doi: 10.1158\/2326-6066.CIR-25-0242. Online ahead of print. ABSTRACT Tumor cells employ metabolic mechanisms to limit antitumor immunity and promote resistance to immunotherapy. However, how immunotherapy modulates tumor metabolism remains unclear. Here, we demonstrated that anti-PD-1 treatment regulated cholesterol biosynthesis in cancer cells through the effector cytokine interferon IFN-\u03b3. Mechanistically, IFN-\u03b3-induced &#8230; <a title=\"Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFN-\u03b3-\u0399RF1-SREBF2 Axis\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/09\/immunotherapy-inhibits-tumor-cholesterol-synthesis-via-the-ifn-%ce%b3-%ce%b9rf1-srebf2-axis\/\" aria-label=\"Read more about Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFN-\u03b3-\u0399RF1-SREBF2 Axis\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/08\/a-universal-boosting-strategy-for-adoptive-t-cell-therapy-using-a-paired-vaccine-chimeric-antigen-receptor\/\">A universal boosting strategy for adoptive T cell therapy using a paired vaccine\/chimeric antigen receptor<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-12-08T19:19:04+01:00\" class=\"wp-block-latest-posts__post-date\">8 de December de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2025 Dec 8. doi: 10.1158\/2326-6066.CIR-25-0070. Online ahead of print. ABSTRACT Vaccines that encode tumour-associated antigens are potent boosting agents for adoptively transferred tumour-specific T cells. Employing vaccines to boost adoptively transferred tumour-reactive T cells relies on a priori knowledge of tumour epitopes, isolation of matched epitope-specific T cells, and personalized vaccines, all &#8230; <a title=\"A universal boosting strategy for adoptive T cell therapy using a paired vaccine\/chimeric antigen receptor\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/08\/a-universal-boosting-strategy-for-adoptive-t-cell-therapy-using-a-paired-vaccine-chimeric-antigen-receptor\/\" aria-label=\"Read more about A universal boosting strategy for adoptive T cell therapy using a paired vaccine\/chimeric antigen receptor\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/05\/t-cell-priming-by-high-avidity-neoantigens-in-lymph-nodes-augments-adoptive-immunotherapy\/\">T cell priming by high avidity neoantigens in lymph nodes augments adoptive immunotherapy<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-12-05T20:44:03+01:00\" class=\"wp-block-latest-posts__post-date\">5 de December de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2025 Dec 5. doi: 10.1158\/2326-6066.CIR-25-0514. Online ahead of print. ABSTRACT Adoptive transfer of T lymphocytes specific for tumor-associated neoantigens can elicit immunity against solid tumors in patients. However, how these antigens impact T cell function, effector differentiation, and persistence remains unclear. We examined how an identical CD8+ T cell product was shaped &#8230; <a title=\"T cell priming by high avidity neoantigens in lymph nodes augments adoptive immunotherapy\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/05\/t-cell-priming-by-high-avidity-neoantigens-in-lymph-nodes-augments-adoptive-immunotherapy\/\" aria-label=\"Read more about T cell priming by high avidity neoantigens in lymph nodes augments adoptive immunotherapy\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/02\/a-sampling-of-highlights-from-the-literature-article-recommendations-from-our-deputy-and-senior-editors-7\/\">A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-12-02T13:41:06+01:00\" class=\"wp-block-latest-posts__post-date\">2 de December de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2025 Dec 2;13(12):1893. doi: 10.1158\/2326-6066.CIR-13-12-WWR. NO ABSTRACT PMID:41327976 | DOI:10.1158\/2326-6066.CIR-13-12-WWR<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/01\/the-pleiotropic-roles-of-cytokines-in-chimeric-antigen-receptor-t-cell-therapy\/\">The Pleiotropic Roles of Cytokines in Chimeric Antigen Receptor T-cell Therapy<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-12-01T18:47:33+01:00\" class=\"wp-block-latest-posts__post-date\">1 de December de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2025 Dec 1:OF1-OF12. doi: 10.1158\/2326-6066.CIR-25-0631. Online ahead of print. ABSTRACT Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of cancer. However, the durable response to this therapy remains low, and there is a risk of moderate-to-severe toxicities following treatment that requires close monitoring. Over the past decade, we have learned &#8230; <a title=\"The Pleiotropic Roles of Cytokines in Chimeric Antigen Receptor T-cell Therapy\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/01\/the-pleiotropic-roles-of-cytokines-in-chimeric-antigen-receptor-t-cell-therapy\/\" aria-label=\"Read more about The Pleiotropic Roles of Cytokines in Chimeric Antigen Receptor T-cell Therapy\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/26\/pyroptosis-modulates-multiple-immune-cell-populations-in-targeted-therapy-treated-melanoma\/\">Pyroptosis modulates multiple immune cell populations in targeted therapy-treated melanoma<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-26T19:48:19+01:00\" class=\"wp-block-latest-posts__post-date\">26 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2025 Nov 26. doi: 10.1158\/2326-6066.CIR-25-0444. Online ahead of print. ABSTRACT Treatment of melanoma with BRAF inhibitors plus MEK inhibitors (BRAFi + MEKi) stimulates an intratumoral immune response, in part through pyroptosis mediated by the pore-forming protein gasdermin E (GSDME\/Gsdme). How GSDME mediates effects on tumoral immunity is not well characterized. Using single-cell &#8230; <a title=\"Pyroptosis modulates multiple immune cell populations in targeted therapy-treated melanoma\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/26\/pyroptosis-modulates-multiple-immune-cell-populations-in-targeted-therapy-treated-melanoma\/\" aria-label=\"Read more about Pyroptosis modulates multiple immune cell populations in targeted therapy-treated melanoma\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/22\/lymphotropic-virotherapy-induces-dc-and-high-endothelial-venule-inflammation-promoting-the-antitumor-efficacy-of-intratumor-virus-administration\/\">Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-22T00:53:18+01:00\" class=\"wp-block-latest-posts__post-date\">22 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2025 Nov 21. doi: 10.1158\/2326-6066.CIR-25-0756. Online ahead of print. ABSTRACT Tumor-draining lymph nodes are a pivotal site for antitumor T-cell priming. However, their mechanistic roles in cancer immune surveillance and immunotherapy response remain poorly defined. Intratumor (IT) virotherapy generates antitumor T-cell immunity through multifaceted engagement of innate antiviral inflammation. Here we identify &#8230; <a title=\"Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/22\/lymphotropic-virotherapy-induces-dc-and-high-endothelial-venule-inflammation-promoting-the-antitumor-efficacy-of-intratumor-virus-administration\/\" aria-label=\"Read more about Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/22\/tcpgdb-a-comprehensive-t-cell-perturbation-genomics-database-for-identification-of-critical-t-cell-regulators\/\">TCPGdb: A comprehensive T cell perturbation genomics database for identification of critical T cell regulators<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-22T00:53:18+01:00\" class=\"wp-block-latest-posts__post-date\">22 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2025 Nov 21. doi: 10.1158\/2326-6066.CIR-25-0168. Online ahead of print. ABSTRACT Large parallel genetic screens have been used to identified targets and regulators that enhance T cell antitumor capability and persistence in tumor microenvironment. We hypothesized that by combining the pooled screen data from multiple independent genetic screens we could provide a systematic, &#8230; <a title=\"TCPGdb: A comprehensive T cell perturbation genomics database for identification of critical T cell regulators\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/22\/tcpgdb-a-comprehensive-t-cell-perturbation-genomics-database-for-identification-of-critical-t-cell-regulators\/\" aria-label=\"Read more about TCPGdb: A comprehensive T cell perturbation genomics database for identification of critical T cell regulators\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/22\/phenotypic-characterization-and-prognostic-impact-of-cd103-tissue-resident-memory-t-cells-in-diffuse-large-b-cell-lymphoma\/\">Phenotypic characterization and prognostic impact of CD103+ tissue-resident memory T cells in diffuse large B cell lymphoma<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-22T00:53:18+01:00\" class=\"wp-block-latest-posts__post-date\">22 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Cancer Immunol Res. 2025 Nov 21. doi: 10.1158\/2326-6066.CIR-25-0445. Online ahead of print. ABSTRACT Tissue-resident memory T (TRM) cells, memory T cells that stably occupy tissues and contribute to immunosurveillance, induce favorable survival outcomes in solid tumors. While TRM cells have been observed in lymph nodes, their phenotype and prognostic significance in diffuse large B-cell lymphoma &#8230; <a title=\"Phenotypic characterization and prognostic impact of CD103+ tissue-resident memory T cells in diffuse large B cell lymphoma\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/22\/phenotypic-characterization-and-prognostic-impact-of-cd103-tissue-resident-memory-t-cells-in-diffuse-large-b-cell-lymphoma\/\" aria-label=\"Read more about Phenotypic characterization and prognostic impact of CD103+ tissue-resident memory T cells in diffuse large B cell lymphoma\">Read more<\/a><\/div><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":16669,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-16668","page","type-page","status-publish","has-post-thumbnail"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages\/16668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=16668"}],"version-history":[{"count":1,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages\/16668\/revisions"}],"predecessor-version":[{"id":16670,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages\/16668\/revisions\/16670"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media\/16669"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=16668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}